

1 **nELAVL phosphorylation by CDKL5 regulates inter-condensates**
2 **composition and communication to promote experience-dependent**
3 **maturation of the visual cortex**

4
5 Shiyang Yuan^{1,21}, Yao Zhu^{1,21}, Zhongyu Zheng^{1,21}, Hei Matthew Yip^{1,21}, Maggie See Wing
6 Chan¹, Zhongjie Zhang¹, Yue Chai¹, Kyle Robert Jenks², Katya Tsimring², Gregg Robert
7 Heller², Jose Carlos Zepeda³, Marco Celotto², Hung Kwok Hung⁴, Yangyang Duan⁴, Shun-
8 Fat Lau⁴, Crystal Wing Yan Ho⁴, Hayley Wing Sum Tsang⁴, Amy Kit Yu Fu⁴, Hei Ming Lai⁵,
9 Andrew John Kwok^{6,7,8}, Ho Ko^{6,7,8}, Chunbin Gu^{7,9,10}, Billy Wai-Lung Ng^{7,8,9,10}, Jinyue Liao¹¹,
10 Sin Hang Fung¹, Qin Cao¹, Stephen Kwok-Wing Tsui¹, Taeyun Ku¹², Liming Tan^{13,14},
11 Andrea Colarusso¹⁵, Keren Lasker¹⁵, Yihui Wan¹⁶, Jinwei Zhu^{16,17}, Jacque Pak Kan
12 Ip^{1,8,18,19,20,*}

13
14 ¹School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong, China

15 ²Department of Brain and Cognitive Sciences, Picower Institute for Learning and Memory,
16 Massachusetts Institute of Technology, Cambridge, MA, USA

17 ³Department of Pharmacology, Vanderbilt University, Nashville, TN, USA

18 ⁴Division of Life Science, State Key Laboratory of Molecular Neuroscience and Molecular
19 Neuroscience Center, The Hong Kong University of Science and Technology, Hong Kong,
20 China

21 ⁵Department of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong,
22 China

23 ⁶Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of
24 Hong Kong, Hong Kong, China

25 ⁷Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of
26 Hong Kong, Hong Kong, China

27 ⁸Gerald Choa Neuroscience Institute, The Chinese University of Hong Kong, Hong Kong,
28 China

29 ⁹Guangdong-Hong Kong-Macao Joint Laboratory for New Drug Screening, School of
30 Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China

31 ¹⁰Peter Hung Pain Research Institute, Faculty of Medicine, The Chinese University of Hong
32 Kong, Hong Kong, China

33 ¹¹Department of Ophthalmology, LKS Faculty of Medicine, The University of Hong Kong,
34 Hong Kong, China.

35 ¹²Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science
36 and Technology, Daejeon, Republic of Korea

37 ¹³Shenzhen Key Laboratory of Neuropsychiatric Modulation, Shenzhen-Hong Kong Institute
38 of Brain Science, Shenzhen Institutes of Advanced Technology, Chinese Academy of
39 Sciences, Shenzhen, China

40 ¹⁴Guangdong Provincial Key Laboratory of Brain Connectome and Behavior, the Brain
41 Cognition and Brain Disease Institute, Shenzhen Institutes of Advanced Technology, Chinese
42 Academy of Sciences, Shenzhen, China

43 ¹⁵Department of Integrative Structural and Computational Biology, Scripps Research, La
44 Jolla, California, USA

45 ¹⁶Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric
46 Disorders, Shanghai Jiao Tong University, Shanghai, China

47 ¹⁷Department of Nephrology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao
48 Tong University School of Medicine, Shanghai, China.

49 ¹⁸Kunming Institute of Zoology - The Chinese University of Hong Kong (KIZ-CUHK) Joint
50 Laboratory of Bioresources and Molecular Research of Common Diseases, The Chinese
51 University of Hong Kong

52 ¹⁹CUHK Gerald Choa Neuroscience Institute – Oujiang Laboratory Joint Laboratory for
53 Neuroscience and Neurology, Wenzhou, Zhejiang Province, China.

54 ²⁰Lead contact

55 ²¹These authors contributed equally to this work.

56 *Correspondence: jacqueip@cuhk.edu.hk

57

58 **Summary**

59

60 Mutations in Cyclin-Dependent Kinase-Like 5 (CDKL5) cause CDKL5 deficiency disorder
61 (CDD), an X-linked neurodevelopmental condition. Through a phosphoproteomic screen, we
62 identified the neuron-specific nELAVL family of RNA-binding proteins as direct activity-
63 dependent substrates of CDKL5. In support of this regulatory axis, single-nuclei
64 transcriptomics of *Cdkl5* knockout (KO) cortices revealed an enriched reduction in activity-
65 dependent mRNAs. Mechanistically, we show that nELAVL proteins undergo phase
66 separation to form biomolecular condensates, the size of which is gated by CDKL5
67 phosphorylation. Loss of CDKL5 leads to enlarged nELAVL condensates, which exhibit
68 reduced binding affinity for the target mRNA *Fos*, resulting in its accelerated degradation.
69 This disruption extends to inter-condensate communication: phosphodeficient nELAVL show
70 diminished interaction with P-bodies, which themselves become enlarged in CDD mutant
71 iNeurons. Functionally, the absence of nELAVL phosphorylation recapitulates the deficits in
72 experience-dependent visual function observed in *Cdkl5* KO mice. Our findings establish a
73 critical molecular mechanism by which CDKL5-mediated phosphorylation governs mRNA
74 metabolism by tuning the properties of nELAVL condensates and their communication with
75 other biomolecular condensates, ultimately promoting experience-dependent maturation of
76 the visual cortex.

77

78 **Introduction**

79

80 CDD is a severe, X-linked neurodevelopmental disorder caused by loss of function mutations
81 in the *CDKL5* gene¹. Initially categorized as an early-onset-seizure variant of Rett syndrome,
82 CDD is now recognized as a distinct condition with its own ICD-10 code (G40.42). CDD is
83 characterized by a range of neurodevelopmental features including early-onset epilepsy,
84 motor dysfunction, learning disabilities, autistic features and severe neurodevelopmental
85 delay^{2,3}. *CDKL5* is a serine/threonine kinase highly expressed in the brain⁴. *Cdkl5* knockout
86 (KO) mice have been shown to exhibit autistic-like phenotypes, impairments in motor control
87 and fear memory⁵, as well as reduced amplitude of visually evoked potentials and
88 diminished visual acuity⁶. *Cdkl5* KO also exhibit impaired dendritic spine development and
89 microtubule dynamics^{7,8}. Phosphorylation targets of CDKL5 include microtubule-binding
90 proteins EB2 and MAP1S, transcriptional regulators ELOA and SOX9, and the voltage-gated
91 Ca²⁺ channel Cav2.3^{7,9-12}. However, clinically relevant phenotypes of CDD rodent model
92 such as motor deficit or cortical visual impairment were not fully recapitulated in the
93 phospho-deficient knock-in mouse models of the abovementioned CDKL5 phosphorylation
94 targets^{7,13}, suggesting that critical CDKL5-mediated functions or phosphorylation targets
95 remain undiscovered.

96 Here, we present evidence that CDKL5 regulates the refinement of binocular visual
97 circuits in mouse V1 through a previously unidentified phosphorylation target. We performed
98 an unbiased phosphoproteomic screen and identified a family of RNA-binding proteins

99 (RBPs), the neuronal Embryonic Lethal, Abnormal Vision-Like proteins (nELAVLs), as
100 direct substrates of CDKL5. The nELAVL proteins, identified as being recruited into
101 ribonucleoprotein (RNP) granules¹⁴⁻¹⁶, play crucial roles in regulating RNA stability,
102 localization, and activity-dependent translation^{17,18}.

103 Considering that post-translational modifications, such as phosphorylation, can
104 impact the phase transition of RNP granules, we postulated that CDKL5-mediated
105 phosphorylation would modulate the propensity of nELAVLs to form condensates.
106 Supporting this hypothesis, we found that nELAVL positive condensates are aberrantly
107 enlarged in *Cdkl5* KO neurons. Furthermore, we observed that CDKL5-mediated
108 phosphorylation also affects the size of other biomolecular condensates, including those
109 labelled with Processing (P)-body marker GW182 and stress granules marker TIA1,
110 suggesting that CDKL5 is a key gatekeeper for fine-tuning condensate properties. Consistent
111 with this notion, we found that mRNA levels of various activity-dependent genes were
112 reduced in the V1 of *Cdkl5* KO mice, linking these molecular changes to the impaired
113 binocular matching of visual responses. Mechanistically, phospho-deficient mutant of
114 ELAVL3 exhibited reduced binding affinity with its target mRNA *Fos* resulting in faster
115 degradation. Functionally, we demonstrate that the orientation selectivity and binocular
116 matching of visual responses is impaired in *Cdkl5* KO mouse V1 neurons with the ipsilateral
117 eye responses more severely affected. Furthermore, we showed that AAV-mediated
118 expression of nELAVL phospho-deficient in mouse bV1 recapitulated the deficits observed
119 in *Cdkl5* KO mice.

120 Taken together, these findings are consistent with a model of cortical visual
121 impairment in CDD in which enlarged nELAVL condensates hampers activity-dependent
122 mRNA regulation, thereby impairing orientation selectivity and binocular matching of V1
123 neurons.

124

125 **Results**

126

127 **CDKL5 phosphorylates nELAVLs in an activity-dependent manner**

128

129 Cortical visual impairment is a phenomenon common amongst neurodevelopmental
130 disorders^{6,19-25}. In particular, amongst the 75% of individuals diagnosed with Cyclin-
131 Dependent Kinase-Like 5 (CDKL5) deficiency disorder (CDD)^{4,6,21,26-30}, an X-linked
132 neurodevelopmental disorder attributed by loss of function mutations in the *CDKL5* gene¹,
133 cortical visual impairment correlates with delayed developmental milestones and has
134 therefore been proposed to be a potential biomarker²¹. Given the clinical relevance of the
135 primary visual cortex (V1), we first sought to identify relevant direct substrates of CDKL5 by
136 applying an unbiased phosphoproteomic screen using V1 tissue from WT and *Cdkl5* KO
137 mice. We used Tandem Mass Tag-based phosphoproteomics analysis and identified 9048
138 phosphopeptides on 3146 phosphoproteins in V1 (Figure 1A; table S1). Among them, 119
139 phosphopeptides were upregulated and 105 downregulated in *Cdkl5* KO mice, corresponding
140 to 88 and 73 phosphoproteins, respectively (Figure 1B). The number and distribution of
141 phosphorylation sites on all identified proteins were analyzed (Figure S1A & B). Gene
142 Ontology (GO) analysis showed that the downregulated phosphopeptides in V1 were
143 predominantly related to synaptic function or structural constituent of the postsynaptic
144 density (Figure 1C). Seven of the downregulated phosphorylated proteins contained the
145 CDKL5 consensus phosphorylation sequences, Arg-Pro-X-Ser-Ala (RPXS*A) or Arg-Pro-X-
146 Ser (RPXS*)³¹, suggesting they are potentially direct substrates of CDKL5 (Figure S1C).
147 nELAVLs were the most significantly down-regulated phosphorylated proteins among these,
148 and the phosphorylation sites on ELAVL2 (S119), 3 (S119) and 4 (S131) are evolutionary

149 conserved among human, mouse, and rat (Figure 1D). ELAVL2, ELAVL3 and ELAVL4
150 have 80% sequence homology, are predominantly expressed in the nervous system and are
151 therefore collectively referred as nELAVLs³². nELAVLs bind to AU-rich elements in a wide
152 range of target mRNAs to regulate RNA stability, localization, and translation^{17,18,33}.

153 To validate that CDKL5 can phosphorylate nELAVLs, we generated a
154 phosphospecific antibody targeting these identified sites. We also obtained a wild-type (WT)
155 EGFP-nELAVLs expression construct and generated a phospho-deficient mutant (nELAVLs
156 SA) with the putative serine phosphorylation site replaced by alanine. We confirmed the
157 specificity of nELAVLs antibodies via Western Blot (Figure S1D). Co-expression of CDKL5
158 and EGFP-ELAVL2, 3 or 4 in HEK 293T cells all showed nELAVL phosphorylation, while
159 phosphorylation was absent when co-expressing CDKL5 and the phospho-deficient mutants
160 (Figure 1E). We also found that nELAVL phosphorylation was consistently reduced in the
161 visual, motor and frontal cortex of *Cdkl5* KO mice (Figure 1F & G). These results show that
162 nELAVL proteins are previously unidentified and *bona fide* CDKL5 phosphorylation targets.

163 Visual experience plays an essential role in V1 development, including the refinement
164 and matching of input from the contra and ipsi eyes³⁴. To test whether phosphorylation of
165 nELAVLs by CDKL5 is experience-dependent, mice were kept in the dark for 16 hours and
166 re-exposed to light for 0, 1 or 2 hours. nELAVLs phosphorylation was significantly higher
167 after 1-hour of light re-exposure but not after 2-hour light re-exposure, suggesting the level of
168 nELAVLs phosphorylation is experience-dependent within a tight time window (Figure 1H
169 & I). Is experience-dependent phosphorylation in V1 specific to nELAVLs, or is this a
170 general feature of CDKL5 substrates? EB2 and MAP1S are two previously reported CDKL5
171 substrates that are involved in microtubule regulation¹⁰. We measured the phosphorylation
172 level of MAP1S and EB2 in V1, and found that the phosphorylation level of MAP1S and
173 EB2 were indeed decreased in *Cdkl5* KO mice compared to WT (Figure S1E & G). However,
174 MAP1S and EB2 phosphorylation levels did not show similar changes as nELAVLs
175 phosphorylation after 1-hour and 2-hour light re-exposure, suggesting MAP1S and EB2
176 phosphorylation in V1 is not experience-dependent *in vivo* (Figure S1F & H).

177

178 **CDKL5 deletion alters expression of activity-dependent genes in V1.**

179

180 Given that nELAVLs are RNA binding proteins involved in the regulation of mRNA stability
181 and translation³³, an important question is how the aberrant phosphorylation of nELAVLs
182 observed in CDKL5 deficiency impacts the expression of relevant mRNAs within mouse V1.
183 Thus, we first used bulk RNA sequencing to profile the transcriptomic differences between
184 WT and *Cdkl5* KO mouse V1. We identified 218 downregulated genes and 272 upregulated
185 genes in *Cdkl5* KO mice when compared to WT mice (Figure 2A & S2A; table S2). Eight
186 selected differentially expressed genes (DEGs) identified by bulk RNA sequencing, including
187 *Arc*, *Fos*, *Npas4*, *Pcdh19*, *Homer1*, *Gad1*, *Sst*, and *Pvalb*, were validated using real-time
188 qPCR (Figure S2B). All the DEGs were submitted to STRING to construct a Protein-Protein
189 interaction (PPI) network. The MCC algorithm in CytoHubba plugin was used to identify hub
190 genes in the PPI network. The top ten genes with the highest MCC scores, including *Fos*,
191 *Nr4a1*, *Egr1*, *Fosb*, *Junb*, *Dusp1*, *Egr2*, *Egr3*, *Fosl2* and *Btg2*, were visualized (Figure 2B).
192 These ten genes are all immediate early genes, suggesting that immediate early genes may
193 play an important role in CDD pathophysiology. Consistently, the Gene Set Enrichment
194 Analysis suggests that many activity-dependent neuronal functions, which are known to be
195 driven by visual experience in V1, are impaired in *Cdkl5* KO mice, including regulation of
196 synapse organization, glutamatergic synapses and dendritic spine development (Figure S2C).

197 To validate whether CDKL5 deficiency could lead to dendritic spine deficits in V1,
198 sparsely labeled layer 2/3 and layer 5 excitatory neurons were analyzed by applying epitope-

199 preserving Magnified Analysis of Proteome (eMAP) (Figure S3A-F). In layer 2/3 neurons,
200 we found that the total dendritic spine density of basal and apical dendrites was lower in
201 *Cdkl5* KO mice. In contrast, in layer 5 neurons, we only observed a significant difference in
202 the spine density of basal dendrites (Figure S3G-J). To further investigate the changes in
203 spine morphology, we compared the density of mushroom-shaped, thin, and stubby spines as
204 well as filopodia between WT and *Cdkl5* KO mice. In layer 2/3 neurons, we found that
205 mushroom-shaped spine density was reduced in *Cdkl5* KO mice on both apical and basal
206 dendrites. In layer 5 neurons, only the density of mushroom-shaped spines on basal dendrites
207 decreased in *Cdkl5* KO mice while on apical dendrites, the density of filopodia was higher in
208 *Cdkl5* KO (Figure S3G-J). These findings indicate that *Cdkl5* KO mice have altered spine
209 density and morphology on excitatory neurons, with a more pronounced effect observed in
210 layer 2/3 neurons.

211 To investigate potential differential effects on specific neuronal layers like layers 2/3
212 and 5, we conducted single nucleus (sn) RNA sequencing to compare the transcriptomes of
213 WT and *Cdkl5* KO V1. Nuclei from 6 snRNA libraries of V1 were collected from 6 WT and
214 6 *Cdkl5* KO mice and the gene expression matrices were filtered to remove low-quality cells
215 and cells containing a high proportion of mitochondrial transcripts (>5%). Doublets were
216 identified using Scrublet³⁵ and removed in the downstream analysis (Figure S4A) and
217 Harmony³⁶ was applied for batch correction (Figure S4B). We obtained 62051 high-quality
218 cells from the 6 snRNA libraries and combined them for the downstream analysis.
219 Dimensionality reduction and Leiden clustering were applied to generate different cell classes,
220 subclasses and types (Figure 2C & S4E-G). Classes consisted of glutamatergic neurons
221 (37289 cells), GABAergic neurons (7318 cells) and non-neuronal cells (17444 cells). The
222 UMAP of overlapping WT and *Cdkl5* KO libraries showed no gross change in cell types
223 (Figure S4C & D).

224 Next, we performed differential gene expression analysis between the nuclei from
225 WT and *Cdkl5* KO V1. Interestingly, we identified 69 activity-dependent genes among the
226 458 total DEGs in *Cdkl5* KO mice (Figure 2D; table S3), and ~50% of these overlapped with
227 activity-dependent DEGs identified in bulk RNA sequencing (Figure S4O), and among these
228 29 activity-dependent DEGs, 22 are overlapped with nELAVL-binding mRNAs identified
229 previously³³ (Figure S4P), again suggesting that activity-dependent plasticity might be
230 disrupted by loss of CDKL5. We found that CDKL5, and its phosphorylation targets the
231 nELAVLs, are mainly expressed in glutamatergic neurons (Figure 2E & S4H) which make
232 up the majority of cells in our dataset (Figure S4D). Therefore, we further analyzed
233 glutamatergic subclasses (Figure S4I), and plotted the number of DEGs in the individual
234 glutamatergic cell types (Figure 2F; table S4). L2/3, L4 and L6 cell types have the most
235 DEGs in *Cdkl5* KO mice. We intersected DEGs in different subtypes with activity-dependent
236 genes and found that significant enrichment among DEGs in L2/3 sublayers (Figure 2G).

237 L2/3 glutamatergic neurons exhibit spatial segregation and display graded gene
238 expression across three sublayers (A, B, and C). L2/3_A is adjacent to the pia, L2/3_C
239 borders L4 and L2/3_B is positioned between L2/3_A and L2/3_C. This segregation
240 represents an activity-dependent maturation of the layer and can be disrupted by dark
241 rearing³⁷. The laminar distribution of these sublayer neurons has been suggested to related to
242 different downstream projecting targets and functions^{38,39}. Given the deficits in layer 2/3
243 neurons identified through dendritic spine analysis, we were intrigued to investigate whether
244 transcriptomic maturation of layer 2/3 neurons is influenced by the deletion of CDKL5.
245 Therefore, we separated L2/3 glutamatergic neurons from WT and *Cdkl5* KO V1 into three
246 types (A, B, and C) (Figure S4J & K) according to the sublayer-specific marker
247 *Cdh13*, *Trpc6*, and *Chrm2*³⁷. We found that the cell proportions across three sublayers of
248 neurons was unchanged (Figure S4L), but significant transcriptomic alterations were

249 observed. Again, we highlighted several activity-dependent downregulated DEGs (Figure 2H)
250 including *Homer1*, *Syt4*, *Tubala*, *Nptx2*, *Per1*, *Arc*, *Prickle1*, as well as the L2/3_A sublayer
251 marker *Cdh13*, which are all documented to associate with neuronal plasticity⁴⁰⁻⁴⁷. Among
252 the highlighted DEGs, *Homer1*, *Syt4*, *Tubala* were found to be common across all sublayers
253 of L2/3. *Cdh13* was uniquely identified as a DEG in sublayer L2/3_A, as expected, while
254 *Nptx2* and *Per1* were specific DEGs in L2/3_B. *Arc* was found to be significantly
255 downregulated in L2/3_B and L2/3_C whereas *Prickle1* was exclusively identified as a DEG
256 in L2/3_C. These findings suggest distinct molecular signatures associated with each
257 sublayer, indicating potential disruptions in the specialized functional roles within L2/3
258 sublayers following CDKL5 deletion, without affecting the overall cell proportions of layer
259 2/3 neurons.

260 In addition, we also analyzed inhibitory neurons and found their composition also did
261 not show any significant difference between groups (Figure S4M). However, when
262 computing DEGs in different types of inhibitory neurons, we found that most DEGs were
263 specific to Pvalb+ inhibitory neurons (Figure S4N).

264 To validate whether the activity-dependent DEGs identified in bulk and snRNA
265 sequencing are decreased in *Cdkl5* KO mice, we used fluorescence in-situ hybridization
266 (FISH). We found that mRNA expression levels of *Fos*, *Homer1* and *Arc* were indeed
267 significantly reduced in *Cdkl5* KO mice while *Camk2a*, an excitatory neuron marker, was
268 unaltered (Figure 2I & J). Immunostaining results also showed that the expression of c-fos
269 was decreased significantly in layers 2/3, 4 and 6 in *Cdkl5* KO mice (Figure S4Q & R). Of
270 note, the *Fos* mRNA punctum volume in *Cdkl5* KO mice appeared larger than those in WT
271 mice (Figure 2I & J).

272 Taken together, the structural abnormalities in dendritic spines (Figure S3) align with
273 the decreased expression of activity-dependent genes and excitatory synaptic mRNA as
274 revealed in our transcriptomic analysis (Figure 2A). Notably, 21 out of 29 dysregulated
275 activity-dependent genes (highlighted in Figure 2D), including *Fos* and *Homer1*, are direct
276 binding targets of nELAVLs identified through CLIPseq analysis³³. These observations led
277 us to postulate that the CDKL5-mediated phosphorylation of nELAVLs modulates the
278 mRNA levels of activity-dependent genes, thereby influencing the refinement of the visual
279 circuit.

280

281 **Loss of CDKL5-mediated phosphorylation alters nELAVLs phase separation**

282

283 We next sought to investigate how phosphorylation of nELAVLs by CDKL5 affects mRNA
284 expression in mouse V1. While CDKL5 itself was found to undergo phase separation⁴⁸, we
285 therefore evaluate the phase separation propensity of CDKL5's kinase target nELAVLs. We
286 employed the LLPhyScore algorithm⁴⁹ to analyze a composite dataset comprising these target
287 sequences alongside a benchmark set of experimentally verified LLPS-positive drivers (e.g.,
288 FUS, TDP-43, TIA-1) and a broad background of negative control sequences (Figure S5).
289 The comparative ranking analysis indicates that nELAVL proteins possess a significant
290 intrinsic potential for phase separation, distinct from non-phase-separating background
291 proteins. While canonical "scaffold" proteins such as FUS and TDP-43 cluster at the apex of
292 the distribution with near-maximal scores (≈ 1.0) and top-tier rankings (Rank < 200), the
293 nELAVLs occupy a prominent intermediate-to-high probability tier. nELAVLs exhibit scores
294 ranging from approximately 0.70 to 0.85, positioning them within the top quartile of the
295 distribution (approximate ranks 700–1300) (Figure S5). Although they do not reach the
296 saturation levels of primary drivers, their significant deviation from the tail of the distribution
297 suggests they encode sufficient multivalent interaction valency to participate in phase
298 separation, likely functioning as client proteins recruited into condensates or driving phase

299 transitions under specific physiological conditions rather than acting as constitutive scaffolds.
300 For example, post-translational modification like phosphorylation can finetune the phase
301 separation features of proteins⁵⁰. To examine whether nELAVLs show different protein
302 distribution with or without CDKL5, we employed expanded V1 tissue of WT and *Cdkl5* KO
303 mice by eMAP. We immunolabelled nELAVLs using a pan-nELAVLs antibody and
304 ELAVL3 using a ELAVL3 specific antibody available (Figure S1D). We found that the
305 immunolabelled signals formed cytoplasmic puncta in V1 neurons (Figure 3A). Although the
306 number of puncta in each neuron showed no significant change, the volume of these puncta
307 were significantly increased in volume in *Cdkl5* KO V1 neurons (Figure S6A). By fraction
308 analysis, we also showed that the volume fraction distribution of these puncta in each neuron
309 has significantly right shifted in *Cdkl5* KO mice, providing evidence that each of the KO V1
310 neurons contains larger nELAVL puncta as compared to WT V1 neurons (Figure 3B). A
311 similar phenotype was observed in the *CDKL5* knockdown primary neurons (Figure S6B &
312 C). These unexpected findings suggested that nELAVLs are involved in droplet-like puncta
313 in cells, and the punctum size is regulated by phosphorylation of nELAVLs by CDKL5.

314 To test the dependence of droplet-formation on nELAVL phosphorylation by CDKL5,
315 we employed phospho-mimetic and phospho-deficient mutations of nELAVLs (SE and SA
316 mutants with the consensus CDKL5 phosphorylation motif of -RPSSA- was substituted with
317 -RPSEA- and -RPSAA-, respectively), to evaluate their capacity to form the droplet-like
318 puncta. We overexpressed GFP-tagged nELAVL-SE and nELAVL-SA in both primary
319 neurons and HEK 293T cells (Figure 3C & S6D, G & I). We first verified that the exogenous
320 nELAVL proteins showed equal expression by immunoblotting (Figure S6E). Subsequently,
321 through stimulated emission depletion (STED) microscopy, we visualized the cellular
322 distribution of nELAVL proteins and showed that the volume of ELAVL3-SA and ELAVL4-
323 SA puncta were significantly larger than that of ELAVL3-SE and ELAVL4-SE puncta,
324 respectively, in both primary neurons and HEK 293T cells (Figure 3C & S6F-J), supporting a
325 critical role of CDKL5-mediated phosphorylation in regulating nELAVL punctum size.

326 The liquid-like nature of the nELAVL puncta was corroborated through live-cell
327 imaging. As we observed similar droplet-like puncta among three nELAVLs, we selected
328 ELAVL3 as a key example to demonstrate their biophysical property. Smaller ELAVL3-SA
329 puncta were found to rapidly coalesce into larger ones over time, suggesting a liquid-like
330 nature (Figure 3D). To evaluate the fluid-like property of the nELAVL puncta, fluorescence
331 recovery after photo-bleaching (FRAP) were performed in HEK 293T expressing ELAVL3
332 SA and SE mutants (Figure 3E & F). The FRAP assays showed that both the SA and SE
333 mutants within these puncta were capable of exchanging with the surrounding cytoplasm. It
334 is worth noting that the recovery rate of SA was much slower than that of SE; within 40
335 seconds, the recovery rate of SA was approximately 35%, while that of SE was around 60%
336 (Figure 3E & F). These data indicated that nELAVL is a member of cytosolic condensates
337 and that its phosphorylation state modulates the properties of this condensate.

338 We next purified the recombinant full-length ELAVL3 protein and sparsely labeled
339 the purified ELAVL3 with the Cy3 fluorophore. Cy3-labeled ELAVL3 protein formed
340 spherical droplets in solution in a concentration-dependent manner (Figure 3G). These
341 droplets fused quickly with each other over time (Figure 3H). The number of ELAVL3
342 droplets decreased when the salt concentration was elevated (Figure 3I), indicating that
343 electrostatic interaction may contribute to the droplet's formation. The phase diagram
344 demonstrated that the droplets could form at the minimal concentration of 2.5 μ M, which is
345 close to physiological condition (Figure 3J). The *in vitro* FRAP experiment showed that the
346 ELAVL3 droplets exhibited recovery subsequent to photobleaching through protein exchange
347 between the condensed droplets and surrounding solution (Figure 3K), suggesting that the
348 ELAVL3 droplets possess properties characteristic of a phase separated state.

349 Taken together, these biophysical features of nELAVLs are reminiscent of
350 biomolecular condensates in biological systems, indicating that nELAVLs can undergo phase
351 separation *in vitro* and in cells. Moreover, their phase separation characteristics can be
352 modulated by the CDKL5-dependent phosphorylation.

353

354 **CDD patient iPSC-derived neurons form aberrant nELAVLs condensates and altered** 355 **crosstalk with P-bodies and stress granules.**

356

357 To investigate whether nELAVL condensates behavior is altered in the context of CDD, we
358 aimed to characterize the nELAVL condensates in female patient-derived iPSC lines carrying
359 the pathogenic variant 1648C>T (p.R550*) of CDKL5. As controls, we utilized a WT allele-
360 expressing control line from the same patient, as well as another base editing-corrected
361 isogenic control line (Figure 4A). We confirmed that CDKL5 expression was absent in the
362 R550* line-derived neurons (iNeurons) (Figure 4B), rendering it a comparable model to KO.
363 CDKL5 expression was restored in the isogenic control line (Figure 4C). As expected, the
364 phosphorylation levels of nELAVLs were significantly reduced in R550* iNeurons and
365 rescued in the isogenic line (Figure 4D & E). STED images of iNeurons revealed that the
366 volume of ELAVL3 and nELAVL condensates were both significantly increased in the
367 R550* iNeurons than in the control line, and this phenotype was rescued in the isogenic line
368 (Figure 4F & G & S7A). These results demonstrated that nELAVL condensates is regulated
369 by CDKL5-mediated phosphorylation in human CDD iNeurons, suggesting that our
370 observations from CDKL5 deficient mouse neurons are translatable.

371 RNP granules have emerged as crucial regulators of many cellular processes,
372 including transcription and translation⁵¹. Among the RNP granules, P-bodies and stress
373 granules are well documented to regulate RNA processing and are dysregulated in human
374 diseases, including several neurodevelopmental disorders⁵². In addition, aberrant RBPs co-
375 condensation has been reported in neurodegenerative conditions¹⁴. We therefore asked
376 whether dysregulated nELAVL condensates may trigger aberrations in other RNP
377 condensates, such as P-bodies and stress granules to influence RNA processing. To test this,
378 we co-immunolabelled nELAVLs with P-body marker GW182 and stress granules marker
379 TIA1 in CDD iNeurons. We found that P-bodies and stress granules volumes were
380 significantly increased in R550* group and such abnormal increase was rescued in isogenic
381 control group (Figure 4H & I & S7B-D).

382 To further investigate the impact of nELAVL phosphorylation on P-bodies and stress
383 granules dynamics, we co-expressed ELAVL3-SA with GW182 or TIA1 in HT22 cells
384 (Figure S7E & G). Similar to the effects observed in iNeurons, the expression of ELAVL3-
385 SA led to an increased size of GW182 and TIA1 puncta, while the expression of ELAVL3-
386 SE led to decreased size (Figure S7E-H). We next hypothesized that the phosphorylation
387 status of ELAVL3 modulates its interaction with GW182. To test this, we performed co-
388 immunoprecipitation and found that the interaction between GW182 and ELAVL3-SE was
389 significantly stronger than that with the phospho-dead ELAVL3-SA mutant (Figure 4J & K).
390 These results suggest that phosphorylation of nELAVLs not only mediates the formation of
391 their own condensates but also modulates their interaction with other biomolecular
392 condensates, such as P-bodies.

393

394 **CDKL5 modulate mRNA processing by regulating nELAVL condensates**

395

396 P-bodies and stress granules are RNP granules known to regulate mRNA storage,
397 decay, and translation⁵², and dynamically sequester mRNAs as a regulatory site during
398 cellular processes⁵³⁻⁵⁵. To study the impact of nELAVL phosphorylation on RNA processing,

399 we employed FISH assay and puro-PLA assay to examine the mRNA level and translation of
400 *Fos*, a known binding target of nELAVLs⁵⁶. We found reduced *Fos* mRNA puncta in
401 ELAVL3-SA expressed primary neurons compared to ELAVL3-SE expressed neurons
402 (Figure 5A& B). From the puro-PLA assay, we dual-labelled puromycin and Fos protein after
403 the puromycin treatment and found reduced *Fos* translation in ELAVL3-SA expressed
404 primary neurons compared to ELAVL3-SE expressed neurons (Figure S7I & J).

405 Cell-free Electrophoretic Mobility Shift Assay (EMSA) reveals different binding
406 affinities between nELAVL-SE and SA to *Fos* RNA. The recombinant nELAVL proteins
407 formed protein-RNA complexes with *Fos*-Cy5 RNA (Figure 5C). The binding affinity of
408 nELAVL-SE to *Fos* was significantly higher than that of nELAVL-SA to *Fos*, indicating that
409 the phosphorylation status of nELAVLs modulates their binding affinity to target RNA
410 (Figure 5C).

411 To test whether the mRNA stability was altered, we used Actinomycin D to inhibit
412 the transcription at different time point (0, 5, 10, 30, 60 mins) before FISH assay on iNeurons.
413 We found that in R550* iNeurons, the half-life of *Fos* mRNA was significantly shorter than
414 in Control iNeurons (Control: 10.61 vs. R550*: 3.304), suggesting increased mRNA
415 degradation in CDD iNeurons (Figure 5 D & E).

416 Taken together, these findings provide evidence for a mechanistic link between
417 CDKL5-mediated nELAVL phosphorylation and the formation and function of RNP granules
418 which plays important role in mRNA processing.

419

420 **CDKL5 deletion impairs visually guided behavior and visually evoked functional** 421 **responses**

422

423 To determine whether the *Cdkl5* KO mice exhibits behavioral deficits related to cortical
424 visual impairment, we employed the visual cliff task^{57,58}, which is designed to detect
425 impairments in stereoscopic depth perception. In this task, animals were placed on a central
426 platform within an apparatus containing two distinct areas: a “safe side” and a “cliff side”
427 (the later consisting of a glass plate positioned above a sharply dropped, patterned floor)
428 (Figure 6A, left). WT mice with intact stereoscopic vision consistently avoided the “cliff”
429 side, descending approximately 80% from the “safe” side (Figure 6A, right). On the other
430 hand, we found that *Cdkl5* KO mice descended significantly more times from the ‘cliff’ side,
431 suggesting impaired stereoscopic depth perception (Figure 6A, right).

432

433 To investigate how CDKL5 deletion influences neuronal responses and computations in the
434 mouse binocular visual cortex (bV1), we conducted two-photon calcium imaging of layer 2/3
435 neurons expressing the calcium indicator GCaMP6f. The visual stimuli were drifting
436 sinusoidal gratings (8 directions, with 45° increments⁵⁹, 0.08, 0.04 and 0.02 cycle per degree
437 (cpd) at 2Hz temporal frequency) with a 3-second grey screen between grating stimuli,
438 followed by 4-second of natural scenes (Figure 6B). During imaging, mice viewed drifting
439 grating and natural scenes stimuli presented independently to each eye (contralateral [contra]
440 or ipsilateral [ipsi] only eye viewing) or to both eyes (binocular viewing) (Figure 6C & D &
441 J). Consistent with established findings, we observed bV1 neurons exhibited varying
442 responses and preferences for stimulus direction to binocular, ipsi eye, or contra eye viewing
443 (Figure 6C & D & J)^{60,61}. WT and *Cdkl5* KO mice did not differ in their percentage of
444 binocularly responsive or monocularly responsive neurons (Table S5). Individual neurons in
445 V1 are often preferentially activated by specific orientations of grating. Therefore, we next
446 measured these preferences, quantified as an orientation selectivity index (OSI). *Cdkl5* KO
447 mice showed robust and significant decrease in OSI across all three imaging conditions
448 (binocular, contra eye only and ipsi eye viewing) at high spatial frequency (0.08cpd) as

449 compared to WT mice, suggesting that they are overall less selective (Figure 6E). A
450 significant difference in OSI was observed across all three tested spatial frequencies, with
451 0.08cpd having the largest OSI decrease in *Cdkl5* KO mice compared to WT (Figure 6E, S8A
452 & K). There is no difference in neuron response amplitude between WT and *Cdkl5* KO mice
453 except ipsi eye viewing condition with 0.02cpd (Table S6). These results suggested that the
454 cortical visual deficits in *Cdkl5* KO V1 neurons are more sensitive to higher spatial frequency
455 (Figure S8K).

456 Neurons in bV1 that receive inputs from both eyes (contra+ipsi responsive) match
457 specific visual responses from each eye to integrate their visual information, thereby
458 establishing an accurate representation of binocular visual space. The binocular neurons are
459 crucial to visual functions such as disparity and depth perception⁶², and the matching of
460 visual information is highly sensitive to disruption of visual experience or plasticity in
461 development^{63,64}. We therefore examined if binocular matching was altered upon CDKL5
462 deletion. We first examined the relationship between OSI and orientation matching
463 (measured by pairwise signal correlations of their calcium responses between the contra eye
464 and ipsi eye) in WT mice (Figure 6F, left). We observed that neurons with a high OSI
465 ($OSI > 0.5$) in both their contra eye and ipsi eye responses exhibited stronger contra-ipsi
466 orientation matching (blue region in Figure 6F, left). On the other hand, neurons with a low
467 OSI ($OSI < 0.5$) in both their contra eye and ipsi eye responses exhibited weaker contra-ipsi
468 orientation matching (red region in Figure 6F, Left), consistent with published findings^{60,65}.
469 In *Cdkl5* KO mice, we observed a significantly reduced fraction of neurons with high OSI
470 and high contra-ipsi orientation matching (blue region in Figure 6F & G) and an increased
471 fraction of neurons with low OSI and low contra-ipsi orientation matching (red region in
472 Figure 6F & G) as compared to WT mice. This suggested that there was a specific
473 impairment of ipsi eye alignment to contra and binocular orientation preferences in *Cdkl5* KO
474 bV1 neurons. Additionally, we examined the difference in preferred orientation between
475 contra and ipsi responses among binocular neurons in WT and *Cdkl5* KO mice. Of note,
476 contra-ipsi (C/I) response correlation and difference in preferred orientation between contra
477 and ipsi responses are two negatively correlated measurements to examine binocular
478 matching (Figure S8B). We observed that *Cdkl5* KO mice showed significant decrease in C/I
479 responses correlation and significant increase in difference in preferred orientation in grating
480 stimuli at spatial frequency 0.08cpd (Figure 6H & I). Consistent with the OSI results, a
481 milder binocular matching deficit was observed in *Cdkl5* KO bV1 neurons at spatial
482 frequency 0.04cpd (Figure S8C-F), and no significant difference was observed at 0.02cpd
483 (Figure S8G-J). In addition, bV1 neurons in *Cdkl5* KO mice exhibited decreased C/I
484 correlation in response to natural scene stimuli, which represent a more complex visual
485 stimulus class (Figure 6K). In sum, the deletion of CDKL5 results in decreased orientation
486 selectivity and contra-ipsi response matching in the bV1 neurons. These deficits suggest there
487 is impaired integration of ipsi eye input, which matures after contra eye inputs are already
488 established and is experience dependent⁶⁶.

489

490 **CDKL5 deletion disrupts circuit-wide visual information processing**

491

492 To investigate how these single-neuron changes affected the binocular circuit, we computed
493 the information encoding at the network level. We applied a supervised support vector
494 machine (SVM) decoder to estimate the information encoding at a populational level,
495 discriminating all four orientations or two natural scenes in our imaging paradigm. The
496 decoding accuracy in the *Cdkl5* KO mice was consistently lower than in the WT mice at
497 fixed population sizes (Figure S8M), suggesting a reduction in visual information in *Cdkl5*
498 KO mice. To evaluate the binocular matching in the population level, we also trained a

499 decoder based on contra only responses and applied this decoder to the ipsi only responses
500 from the same neuronal populations (Figure S8L). At a spatial frequency of 0.08 and 0.04cpd,
501 contra trained decoding accuracy of ipsi responses was significantly lower in *Cdkl5* KO mice
502 than in WT mice, suggesting that visual information contained in the contra responses was
503 less well matched to ipsi responses in *Cdkl5* KO mice. Thus, the deletion of CDKL5 impairs
504 the encoding of visual information at network level, with more pronounced deficits in ipsi
505 eye responses and matching.

506

507 **Fine balance of nELAVLs phosphorylation level is necessary for normal visual** 508 **processing**

509

510 Finally, to determine if cortical visual deficits in *Cdkl5* KO mouse bV1 could be recapitulated
511 by altering nELAVL phosphorylation, we again performed *in vivo* two-photon calcium
512 imaging in layer 2/3 neurons in the bV1 of WT mice injected with virus containing the
513 nELAVL-WT (WT), the nELAVL-SE phospho-mimetic (SE) or nELAVL-SA phospho-
514 deficient (SA), and also compared with the group without expressing exogenous nELAVL
515 proteins (Ctrl) (Figure 6L & S9A). We found no change in the overall proportion of
516 responsive neurons across the different viewing conditions (Table S5). However, OSI was
517 decreased in each viewing condition for nELAVL-WT, SE and SA injected mice when
518 compared to Ctrl, with OSI lower in SA than in SE injected mice for all viewing conditions
519 in grating stimuli at spatial frequency 0.08, 0.04 and 0.02cpd (Figure 6M & S9B & E), while
520 neuron response amplitude is no difference between SE and SA injected mice (Table S6).
521 Intriguingly, WT injected mice showed higher OSI than SA mice but lower than the OSI of
522 SE mice, suggesting nELAVL phosphorylation level modulates orientation selectivity. We
523 next examined binocular matching in these mice. We observed that both WT and SA injected
524 mice showed decrease in C/I response correlation and increase in difference in preferred
525 orientation in grating stimuli at spatial frequency 0.08cpd, as compared to Ctrl (Figure 6N &
526 O). On the other hand, no significant difference was observed between SE-injected mice and
527 Ctrl group (Figure 6N & O). These suggested that overexpression of nELAVL-WT or their
528 phosphodeficient mutant, but not the phosphomimetic mutant, led to impairment of
529 orientation matching. Similar to *Cdkl5* KO mice, a mild effect was observed at spatial
530 frequency 0.04cpd and no significant difference was observed at spatial frequency 0.02cpd
531 (Figure S9C-D & F-G). For the more complex natural scene stimuli, C/I response correlation
532 was decreased in nELAVL-WT, SE and SA injected mice when compared to Ctrl (Figure 6P),
533 suggesting that binocular matching of complex stimuli is more sensitive to the expression
534 level and phosphorylation status of nELAVLs. At the population level, decoding accuracy
535 was decreased across viewing conditions in WT, SE and SA injected mice at spatial
536 frequency 0.08cpd and natural scene when compared to Ctrl (Figure S9H & I). In sum,
537 expression of nELAVL proteins with different phosphorylation status in V1 are sufficient to
538 replicate the cortical visual deficits observed in *Cdkl5* KO mice.

539

540 **Discussion**

541

542 Sensory processing deficits are a prevailing feature in numerous syndromic developmental
543 disorders. Within the spectrum of developmental disorders, individuals with CDD are notable
544 for their high rate of cortical visual impairment. In this study, utilizing a CDD mouse model,
545 we delineated visual processing deficits of orientation tuning, interocular and monocular-
546 binocular matching, and information encoding in the bV1. Our findings indicate that
547 fundamental features of cortical visual processing, both at the single-neuron and network
548 levels, is compromised in CDD mice, potentially impacting higher-order processing stages

549 encompassing recognition, identification, and memory for visual patterns⁶⁷. The binocular
550 orientation mismatch observed in CDD mice likely diminishes their ability to differentiate
551 similar stimuli and hinders the accurate representation of visual space.

552 At eye-opening in mice at P13-14, bV1 is predominantly composed of contra
553 responsive cells which are already orientation selective³⁴, while ipsi and contra+ipsi
554 responsive cells emerge after eye-opening. The contra+ipsi responsive population later
555 becomes orientation matched by experience-dependent plasticity during the ocular
556 dominance critical period⁶¹. Our work reveals that in adult *Cdkl5* KO mice, both orientation
557 selectivity and contra-ipsi orientation matching compromised, with more severe deficits in
558 ipsi driven responses. L2/3 excitatory neurons in bV1 have been shown to undergo structural
559 synaptic remodelling during the critical period dependent on experience-driven changes in
560 gene expression⁶⁸. We found alterations in L2/3 synaptic density and morphology, as well as
561 the transcriptomic profile of *Cdkl5* KO mouse V1, with gene expression changes most
562 prominent in L2/3 (Figure 2F-H). While the overall cell composition of V1 did not change,
563 mRNA for the canonical immediate early gene *Fos*, a marker for neuronal activation and a
564 direct binding target of nELAVLs, was identified as a hub gene for downregulated activity-
565 dependent DEGs in *Cdkl5* KO mice (Figure 2B). Together, our data suggests that L2/3-
566 mediated circuit impairment in *Cdkl5* KO mice is caused by dysregulated activity-dependent
567 gene expression through the loss of CDKL5-dependent phosphorylation of nELAVLs. The
568 deficits in contra-ipsi matching towards the contra eye further suggest that CDKL5-
569 dependent phosphorylation of nELAVLs is most crucial during the developmental ocular
570 dominance critical period. Given that cortical visual impairment is a well-reported clinical
571 feature in CDD patients and has been suggested to be employed as a functional biomarker of
572 CDD^{6,26}, it will be of clinical interest to assess whether CDD patients also experience deficits
573 in interocular integration.

574 Despite the identification of several physiological substrates, it remained unclear how
575 CDKL5 dysfunction leads to cortical visual impairment at the molecular, cellular and neural
576 circuit levels. Here we identified nELAVLs as direct substrates of CDKL5 and demonstrated
577 that CDKL5-mediated phosphorylation can affect the propensity of nELAVLs to undergo
578 phase separation. Our FRAP assay revealed a decreased exchange rate within ELAVL3
579 condensates in the absence of CDKL5-mediated phosphorylation, suggesting a more compact
580 internal structure and less dynamic property of the condensates. CDKL5-dependent
581 phosphorylation introduces negatively charged phosphate groups into the RPSS*A motif on
582 nELAVLs, modulating charge-patterning critical for phase separation. This charge
583 redistribution disrupts the balance of attractive (e.g., cation- π , π - π) and repulsive forces
584 within nELAVLs, akin to phosphorylation-driven phase separation regulation in other RBPs
585 including FUS and TDP-43 are known to undergo phase separation⁶⁹. The negative charge
586 introduced by phosphorylation may also disrupt hydrogen bonding with adjacent
587 arginine/lysine residues⁷⁰, altering RNA-binding domain conformation. Additionally, as
588 activity-dependent DEGs, *Fos* and *homer1* are direct nELAVLs binding targets³³, and our
589 data demonstrated lower mRNA level of these DEGs, low RNA:RBP ratios may also
590 modulate condensate size⁷¹. Given that impaired nELAVL phosphorylation was also
591 observed in the frontal cortex and motor cortex of *Cdkl5* KO mice, it will be of great interest
592 to examine the roles of nELAVLs dysregulation in other clinically relevant phenotypes of
593 CDKL5 deficiency, including motor and social deficits.

594 Our data highlight a CDKL5-mediated phosphorylation switch of nELAVLs that
595 regulates the crosstalk between the nELAVL condensates and other biomolecular
596 condensates. Stress granules and P-bodies are RNP granules that regulate mRNA
597 processing⁵²⁻⁵⁵. The mRNAs sequestered within stress granules or P-bodies can be
598 translationally repressed and these mRNAs may either re-enter the translation process after

599 granule disassembly^{53,54,72,73} or undergo RNA decay⁷⁴⁻⁷⁷. In CDD models as well as in
600 scenarios where nELAVLs are non-phosphorylated, we observed reduced levels of
601 nELAVLs-binding mRNA concomitant with an augmentation in the volume of nELAVLs,
602 stress granules, and P-bodies puncta. These results suggest that the loss of CDKL5 function
603 in CDD patients leads to a downregulation of nELAVL phosphorylation, which in turn
604 results in abnormal phase separation of nELAVLs. Such aberrant nELAVL phase separation
605 then contributes to dysregulated stress granules and/or P-bodies, which sequester and prevent
606 the activity-dependent translation of key mRNAs essential for synaptic plasticity, ultimately
607 contributing to impaired refinement of neural circuits during the pathological, developmental
608 progression of CDD (Figure S10). To elucidate how aberrant RNP condensates—including
609 P-bodies and stress granules—coordinately dysregulate mRNA expression and translation in
610 CDKL5 deficiency will be our future direction.

611 Altered dynamics of stress granules and P-bodies has been suggested to contribute to
612 the pathology of several neurodegenerative conditions including amyotrophic lateral sclerosis,
613 frontotemporal dementia, Alzheimer's disease and Parkinson's disease⁷⁸⁻⁸⁰. Genetic and
614 functional studies also suggest that nELAVLs, stress granules, and P-bodies are strongly
615 implicated in neurodevelopmental disorders. ELAVL3 and ELAVL4 null mice display
616 deficits in learning, motor function, and neuronal maturation⁸¹⁻⁸³. Differential gene
617 expression analysis in ELAVL2 knockdown primary human neurons also reveals autism
618 related alterations⁸⁴. ELAVL3 has also been identified as an autism-associated gene in
619 multiple large-scale genetic studies⁸⁵⁻⁸⁷, and both ELAVL2 and ELAVL3 are listed as autism
620 candidate genes by the Simons Foundation Autism Research Initiative. Similarly, pathogenic
621 variants of genes encoding for stress granules and P-bodies core proteins such as G3BP1,
622 UBAP2L and TNRC6B have been identified in patients with neurodevelopmental
623 disorders^{88,89}. Given the pivotal roles of nELAVLs in a wide range of neurological disorders,
624 it is reasonable to speculate that the dysregulation of CDKL5-mediated phosphorylation of
625 nELAVLs, and the subsequent formation of aberrant nELAVL condensates, may also
626 contribute to the etiology of other diseases.

627 In summary, our findings shed light on the physiological significance of CDKL5-
628 mediated nELAVLs phase separation, as well as their interplay with other biomolecular
629 condensates, in the context of activity-dependent visual circuit refinement. These findings
630 deepen our understanding of the link between CDKL5 loss of function and cortical visual
631 impairment in CDD, and potentially other pathology. Crucially, our discovery also opens up
632 possibilities for exploring how phosphorylation governs the crosstalk among various
633 biomolecular condensates which have broad and profound implications for normal brain
634 function as well as neurodevelopmental and neurodegenerative disorders.
635
636

637 **Acknowledgments**

638 We thank Gavin Siu, Josie Lai, Joaquim Vong and Cara Kwong for their technical assistance.
639 We also thank Core Laboratories, School of Biomedical Sciences, the Chinese University of
640 Hong Kong as well as Biosciences Central Research Facility, the Hong Kong University of
641 Science and Technology for their technical support. We thank Hei Man Kim Chow for
642 sharing HEK 293T and HT22 cells. We thank Hovy Wong and Kwok-On Lai for critical
643 comments on the manuscript.

644
645 **Author contributions**

646 S.Y. performed surgeries, two-photon imaging, phosphoproteomic and eMAP experiments.
647 Y.Z. performed RNA extraction, real-time PCR, FISH, bulk and snRNA-seq data analysis.
648 Zhongyu Z. performed cell line, primary neuron and iPSC experiments, STED imaging and
649 quantification. H.Y. processed and analyzed the two-photon imaging data. Zhongjie Z.
650 carried out population analysis for two-photon imaging data. K.J., K.T., G.H., J.Z., Marco C.
651 and L.T. contributed to two-photon imaging data analysis. Maggie C. and Y.C. performed
652 Western blot, with inputs from H.H. Y.D., S.L. and A.F. contributed to snRNA-seq
653 experiments. C.H., H.T. and Zhongyu Z. performed FRAP experiments. H.L. and H.K.
654 provided expertise on the FISH experiment. J.L., A.K., S.F., Q.C. and S.T. contributed to
655 snRNA-seq analysis. T.K. provided expertise on eMAP experiments. A.C. and K.L. provided
656 expertise on cellular condensates experiments. C.G. and B.N. computed the phase separation
657 propensity of nELAVLS. Y.W. and J.Z. performed the in vitro phase separation assay. J.I.
658 conceived and supervised all aspects of the experiments. S.Y., Y.Z., Zhongyu. Z., H.Y. and
659 J.I. wrote the paper. All authors edited the manuscript.

660
661 **Funding**

662 This work was supported by STI2030-Major Projects (2022ZD0214400; J.I., J.Z), Research
663 Grants Council (RGC) of Hong Kong SAR (24117220, J.I.; C4005-24Y, J.I.), a research
664 grant from the University of Pennsylvania Orphan Disease Center on behalf of the Loulou
665 Foundation (J.I.; K.L.), Guangdong Basic and Applied Basic Research Foundation
666 (2022B1515130007; J.I.), the National Research Foundation of Korea (RS-2023-00264980;
667 T.K.), Lo Kwee-Seong Biomedical Research Fund (J.I.), Faculty Innovation Awards
668 (FIA2020/A/04; J.I.) from the Faculty of Medicine, CUHK (J.I.) and Gerald Choa
669 Neuroscience Institute Research Program Fund (J.I.).

670
671 **Declaration of interests**

672 The authors declare no competing interests.

673
674 **Methods**

675
676 **Key Resources Table**

677

Antibodies	Source	Catlog #
Rabbit anti-ELAVL2	Proteintech	14008-1-AP
Rabbit anti-nELAVL pS	Biomatik	custom-made
Rat anti-EB2	Abcam	ab45767
Rabbit anti-EB2 pS222	Covalab	00117741

Rabbit anti-MAP1S	Sigma	HPA050934
Rabbit anti-MAP1S pS812	Covalab	00118044
Mouse monoclonal anti-GAPDH	Invitrogen	AM4300
Mouse monoclonal anti-CDKL5	Santa Cruz	sc-376314
Rabbit monoclonal anti-c-fos	Synaptic Systems	226008
Chicken polyclonal anti-GFP	Invitrogen	A10262
Rabbit polyclonal anti-ELAVL3 (HuC)	Proteintech	55047-1-AP
Mouse monoclonal anti-ELAVL4 (HuD)	Santa Cruz	sc-48421/sc-28299
Mouse monoclonal anti-GW182	Santa Cruz	sc-56314
Mouse monoclonal anti-TIA1	Santa Cruz	sc-166247
Goat anti-chicken, Alexa 488	Invitrogen	A32931
Goat anti-rabbit, Alex 555	Invitrogen	A32732
Goat anti-mouse, Alex 647	Invitrogen	A32728
Goat anti-rabbit, Alex 647	Invitrogen	A32733
Abberior STAR ORANGE	Abberior	STORAGE
Abberior STAR RED	Abberior	STRED

678

Bacterial and virus strains	Source	Catlog #
rAAV-hSyn-GCaMp6f-WPRE-hGH polyA	Brain VTA	PT-0147
AAV9-hSyn-nElavl-P2A-DsRed-WPRE-BGH-polyA	Vigene	/
AAV9-hSyn-nElavl(SE)-P2A-DsRed-WPRE-BGH-polyA	Vigene	/

AAV9-hSyn-nElavl(SA)-P2A-DsRed-WPRE-BGH-polyA	Vigene	/
pCAG-FLEX-EGFP-WPRE	Addgene	51502
pENN.AAV.CamKII 0.4.Cre.SV40	Addgene	105558

679

Experimental Organisms/strains	Source	Catlog #
Mouse: <i>Cdk15</i> KO	The Jackson Laboratory	Strain #:021967; RRID:IMSR_JAX:021967
Mouse: C57BL/6J	Laboratory Animal Services Centre, The Chinese University of Hong Kong	/

680

Software and algorithms	Source	Catlog #
MATLAB	Mathworks	https://www.mathworks.com/products/matlab.html
GraphPad Prism 9	GraphPad Software Inc	https://www.graphpad.com/scientific-software/prism/
Fiji	Open source	https://imagej.net/software/fiji/
Suite2p	Open source	https://suite2p.readthedocs.io/en/latest/
Imaris	Oxford Instruments	https://imaris.oxinst.com/
Python	Anaconda3	https://www.anaconda.com
R	R version 4.1.2	https://www.r-project.org/

681

682 **Resource availability**

683

684 ***Leading contact***

685 Further information and requests for resources and reagents should be directed to and will be
686 fulfilled by the lead contact (jacqueip@cuhk.edu.hk).

687

688 ***Materials availability***

689 This study did not generate new unique reagents.

690

691 ***Data and code availability***

692 Any additional information to reanalyze the data reported in this paper is available upon
693 request. All raw and processed snRNA-seq datasets reported in this study will be available

694 before publication. Analysis code generated during this study are available upon reasonable
695 request.

696

697

698 **Methods details**

699 ***Mouse line***

700 *Cdkl5* KO mouse line⁵ (B6.129(FVB)-*Cdkl5* *tm1.1Jozz* /J, strain no: 02196, Jackson
701 Laboratory) was imported from the Jackson Laboratory. A colony was maintained at the
702 Laboratory Animal Services Centre of the Chinese University of Hong Kong and housed in
703 the Animal Holding Core of the School of Biomedical Sciences, the Chinese University of
704 Hong Kong. *Cdkl5* heterozygous females (+/-) were used as breeders with C57BL/6 wildtype
705 males to produce WT and *Cdkl5* KO littermates. Our study mainly focused on investigating
706 hemizygous male mice as our model to avoid potential confounds induced by mosaic
707 expression of CDKL5 in heterozygous females resulting from random X chromosome
708 inactivation. C57BL/6 mice were used for nELAVLs, nELAVLs-SE, nELAVLs-SA virus
709 injection for two-photon calcium imaging. Mice were group-housed (no more than five mice
710 per cage) with a standard light/dark cycle of 12/12 hours with access to food and water *ad*
711 *libitum*. All experimental procedures were approved by the Animal Experimentation Ethics
712 Committee of The Chinese University of Hong Kong.

713

714 ***Genotyping***

715 A PCR-based method was used to detect deletions in *Cdkl5* exon 6 for genotyping (Phire
716 Tissue Direct PCR Master Mix, Thermo Fisher Scientific). Dilution Buffer and DNA Release
717 from the genotyping kit were mixed for genomic DNA extraction for 5 minutes at 98 °C, 20
718 µl Dilution Buffer and 1 µl DNA Release for each sample. 1 µl of genomic DNA extracted
719 from the ear tissue was used for PCR. Primers for genotyping are forward: 5'-
720 CCACCCTCTCAGTAAGGCAGCAG-3' and reverse: 5'-
721 GTCCTTTTGCCACTCAATTCCATCC-3'⁵. PCR reactions contained 0.5 µl of each primer,
722 10 µl 2X Phire Tissue Direct Master Mix and 8 µl nuclease-free water. PCR was performed
723 using the following program: 1) 95°C for 3 min, 2) 98°C for 20 s, 3) 60°C for 15 s, 4) 72°C
724 for 1 min, 5) 72°C for 2 min, 6) 4°C for 10 min and finish. Repeat steps 2-4 for 27 times. The
725 WT allele showed a 653 base pair product, and the *Cdkl5* KO allele showed a 305 base pair
726 product.

727

728 ***Phosphoproteomics***

729 V1 of 4 pairs WT and of *Cdkl5* KO littermates (8-week old) were processed for TMT
730 labeling by Shanghai Applied Protein Technology Co., Ltd. For protein extraction and
731 digestion, tissues were separately lysed in SDT buffer (4% SDS, 100 mM Tris-HCl, and 1
732 mM DTT [pH 7.6]) and quantified using the BCA Protein Assay Kit. Digested peptides of
733 each sample were sonicated by C18 Cartridges and concentrated by vacuum centrifugation,
734 followed by reconstituting in 40 µl of 0.1% (v/v) formic acid. 280 nm UV light spectral
735 density was used to estimate the peptide content. The peptide mixture of each sample (100 µg)
736 was labeled with TMT (Thermo Fisher Scientific) reagent. Phosphorylated peptides were
737 subjected to TiO₂ bead-based enrichment (90% enrichment efficiency) followed by LC-
738 MS/MS analysis in Thermo Scientific Q Exactive HF mass spectrometer (Thermo Scientific)
739 that was coupled to Easy nLC (Proxeon Biosystems, now Thermo Fisher Scientific) for 120
740 min. The peptides were loaded onto a reverse phase trap column (Thermo Scientific Acclaim
741 PepMap100, 100 µm*2 cm, nanoViper C18) connected to the C18-reversed phase analytical
742 column (Thermo Scientific Easy Column, 10 cm long, 75 µm inner diameter, 3µm resin) in
743 buffer A (0.1% Formic acid) and separated with a linear gradient of buffer B (84%

744 acetonitrile and 0.1% Formic acid) at a flow rate of 300 nl/min controlled by IntelliFlow
745 technology. The mass spectrometer was operated in positive ion mode. MS data was acquired
746 using a data-dependent top10 method dynamically choosing the most abundant precursor ions
747 from the survey scan (300–1800 m/z) for HCD fragmentation. Automatic gain control (AGC)
748 target was set to 3e6, and maximum inject time to 10 ms. Dynamic exclusion duration was
749 40.0 s. Survey scans were acquired at a resolution of 70,000 at m/z 200 and resolution for
750 HCD spectra was set to 17,500 at m/z 200, and isolation width was 2 m/z. Normalized
751 collision energy was 30 eV and the underfill ratio, which specifies the minimum percentage
752 of the target value likely to be reached at maximum fill time, was defined as 0.1%. The
753 instrument was run with peptide recognition mode enabled. For TiO₂ enrichment, samples
754 were reconstituted in pre-cooled IAP Buffer (1.4ml) and followed by adding TiO₂ beads,
755 shaken for 40 minutes and centrifuged to remove the supernatants. Beads were put into the
756 tips and washed with the washing buffer 3 to 6 times. Phosphopeptides were eluted and
757 concentrated using an elution buffer, followed by dissolving in formic acid (20 µl 0.1%) for
758 MS analysis. For LC-MS/MS analysis, a reverse phase trap column connected to a C18-
759 reversed phase analytical column was used to load the peptides. A positive ion mode was
760 used for the mass spectrometer, and MS data were acquired using a data-dependent top10
761 method. Peptides and proteins were mapped by Proteome Discoverer 2.4 (Thermo
762 Electron). The parameters set as follow: Enzyme: Trypsin; Max Missed Cleavages: 2;
763 Variable modifications: Oxidation (M), Phospho (ST) / Phospho (Y); Peptide Mass Tolerance:
764 ± 20 ppm; Fragment Mass Tolerance: 0.1Da; Database pattern: Decoy; Peptide FDR: ≤0.01;
765 Protein FDR: ≤0.01; Experimental Bias: Normalizes all peptide ratios by the median protein
766 ratio. The median protein ratio should be 1 after the normalization. Downregulated genes
767 meeting the criterion of p < 0.05 were selected for GO analysis with all genes we identified in
768 phosphoproteomics as background genes. Top 10 GO terms were mapped, and sequences
769 were annotated using gProfiler.

770

771 ***Western blotting***

772 Samples were collected and homogenized in RIPA lysis buffer supplemented with protease
773 and phosphatase inhibitors, and were incubated for 30 min at 4°C. The resultant lysates were
774 cleared by centrifugation at 20,000g for 20 min at 4°C. Proteins were denatured by 1x sample
775 buffer supplemented with 0.1M DTT and incubated at 95°C for 5-7 min. Samples were then
776 resolved in 10% Tri-glycine SDS-PAGE gel. Proteins were then transferred onto a PVDF
777 membrane at 100V for 2 hr on ice. The membranes were blocked by 5% non-fat milk in TBS
778 and probed with primary antibody diluted in 2% non-fat milk in TBST at 4°C overnight:
779 nELAVL (1:4000, Proteintech), pS-nELAVL (1:1000, Biomatik, rabbit polyclonal
780 phosphospecific antibodies were raised against SYARPS(pS)ASIRDAN), EB2 (1:2000,
781 Abcam), pS222-EB2 (1:2000, Covalab), MAP1S (1:1000, Sigma Aldrich), pS812-MAP1S
782 (1:1000, Covalab), GAPDH (1:7500, Life Technologies), CDKL5 (1:500, Santa Cruz).
783 Following incubation with 1:5000 HRP-conjugated secondary antibody (2% in non-fat milk
784 in TBST) for 1 hr at room temperature, membranes were washed with 1x TBST for five times,
785 and 10 min for each wash. Signal was detected using enhanced chemiluminescent substrate.
786 The expression of targeted proteins was quantified by ImageJ software.

787

788 ***Immunohistochemistry***

789 Mice were perfused with ice-cold phosphate-buffered saline (PBS) and 4% paraformaldehyde
790 transcardially. Brains were collected and incubated in 4% paraformaldehyde at 4°C overnight.
791 Brain was sectioned by vibratome and then subjected to immunostaining. Brain sections were
792 blocked for 1 hr in PBS with 2% horse serum and 0.4% Triton-100 followed by an overnight

793 incubation at 4°C with rabbit anti-c-fos primary antibody (1: 2500, Synaptic Systems). Brain
 794 sections were washed and incubated with a secondary antibody (1: 1000, Invitrogen) for 1 hr
 795 at RT. After PBS rinsing, slices were mounted on glass slides. Confocal microscopy (TCS
 796 SP8, Leica) was used for imaging.

797

798 ***RNA extraction and real-time PCR***

799 Total RNA from mouse V1 was extracted using NucleoSpin RNA kit (Macherey–Nagel),
 800 following the manufacturer’s instructions. Reverse transcription of RNA into cDNA was
 801 conducted using a PrimeScript RT Reagent Kit (RR037A, Takara Bio). Quantitative real-time
 802 PCR was conducted with a Premix Ex Taq Kit (RR390A, Takara Bio) using ABI ViiA7 Real
 803 Time PCR System (Applied Biosystems). The mRNA expression was normalized to that of
 804 *Gapdh*.

805

mouse-Gapdh-Forward primer	TCATGACCACAGTCCATGCC
mouse-Gapdh-Reverse primer	CAGATCCACGACGGACACAT
mouse-Arc-Forward primer	GGAGGGAGGTCTTCTACCGT
mouse-Arc-Reverse primer	CTACAGAGACAGTGTGGCGG
mouse-Fos-Forward primer	CGAAGGGAACGGAATAAG
mouse-Fos-Reverse primer	CTCTGGGAAGCCAAGGTC
mouse-Homer1a-Forward primer	GAAGTCGCAGGAGAAGATG
mouse-Homer1a-Reverse primer	TGATTGCTGAATTGAATGTGTACC
mouse-Homer1b-Forward primer	ACACCCGATGTGACACAGAA
mouse-Homer1b-Reverse primer	CACTGCTTCACATTGGCAGT
mouse-Homer1c-Forward primer	GAGAAGTCGCAGGAGAAGATG
mouse-Homer1c-Reverse primer	TTGCTGAACTAGCATGAGAGAG
mouse-Npas4-Forward primer	CACTCGCAAGGGTGTCTTCT
mouse-Npas4-Reverse primer	AATCCAGGTAGTGCTGCCAC
mouse-Pcdh19-Forward primer	CAGCTTTCGCATTACGGCTC
mouse-Pcdh19-Reverse primer	TAGGTGGACTCGCCAAACAC
mouse-Gad1-Forward primer	TGCTTCCAGCTAAGAACGGG
mouse-Gad1-Reverse primer	CAGAACCTTGGTGGAGCGAT
mouse-Sst-Forward primer	CCCCAGACTCCGTCAGTTTC
mouse-Sst-Reverse primer	GGCTCCAGGGCATCATTCTC

mouse-Pvalb-Forward primer	GCAGACTCCTTCGACCACAA
mouse-Pvalb-Reverse primer	CCTTCTTCACCTCATCCGGG

806

807 ***Bulk RNA sequencing and data analysis***

808 RNA was extracted from V1 tissues of 6 pairs WT and *Cdkl5* KO mice (8-week-old) using
809 NucleoSpin RNA column (Macherey–Nagel), and RNA integrity was assessed by Agilent
810 4200 TapeStation System. mRNA enrichment fragmentation and cDNA library construction
811 were performed by Novogene Co. The transcriptomic profile for each sample was generated
812 by Novogene Co utilizing the Illumina Novaseq 6000 platform, 150bp paired-end sequencing.
813 For RNA sequencing, quality control of the datasets was firstly performed using FastQC⁹⁰.
814 Reads alignment was performed by HISAT2⁹¹ and counting was conducted by
815 FeatureCounts⁹². Differential gene expression analysis was performed using R package
816 DESeq2⁹³. DEGs between WT and *Cdkl5* KO mice were selected using the following criteria:
817 foldchange > 1.2 or < -0.83 and *padj* < 0.05. STRING was used to construct PPI
818 network for DEGs. The PPI network with minimally required interaction score of high
819 confidence (0.7) were visualized in Cytoscape (3.10.0). Maximal Clique Centrality (MCC)
820 algorithm in CytoHubba was used to calculate and identify hub genes. DEGs with
821 log2Foldchange were subjected to GSEA, which was performed by clusterProfiler⁹⁴ that
822 enabled GO term enrichment analysis.

823

824 ***Isolation of V1 nuclei for snRNA-seq***

825 Nuclei from 6 pairs of frozen WT and *Cdkl5* KO mouse (8-week-old) V1 samples were
826 isolated following previously established protocol⁹⁵. WT and *Cdkl5* KO mice were
827 euthanized as described above. Mouse V1 was dissected in ice-cold DPBS and immediately
828 snap-frozen in liquid nitrogen. Frozen V1 tissues from two animals were pooled and
829 transferred to a prechilled Dounce homogenizer containing ice-cold homogenization buffer.
830 This buffer consisted of 250 mM sucrose, 25 mM KCl, 5 mM MgCl₂, 20 mM tricine-KOH
831 (pH 7.8), 1 mM dithiothreitol, 0.15 mM spermine, 0.5 mM spermidine, 5 µg/mL actinomycin,
832 0.16% Nonidet P-40, 0.04% bovine serum albumin, protease inhibitors, and 200 U/mL
833 RNAsin. The tissues were gently homogenized on ice using a loose pestle until no visible
834 solid fragments remained. The lysate was subsequently combined with OptiPrep (Sigma) at a
835 ratio of 1:1 (v/v) and centrifuged at 10,000 × *g* for 20 min at 4 °C. The supernatant was
836 removed and the nuclei were washed once with Dulbecco's modified Eagle medium/F12
837 supplemented with 5% fetal bovine serum. The nuclei were resuspended in Dulbecco's
838 modified Eagle medium/F12 supplemented with 10% fetal bovine serum and 200 U/mL
839 RNAsin. The resuspended nuclei were counted on a hemocytometer using Trypan blue
840 labeling and diluted to 400 nuclei per microliter. Nuclei were recounted on an automated cell
841 counter (RWD) before further processing.

842

843 ***snRNA-seq library preparation***

844 snRNA-seq libraries of WT and *Cdkl5* KO mouse V1 samples were constructed by
845 Chromium Single Cell 3' Library Kit v3 (1000078; 10× Genomics). 40 µL suspension of
846 diluted nuclei for each sample was loaded and processed according to manufacturer's
847 instructions. The libraries were subjected to 150bp paired-end sequencing on an Illumina
848 NovaSeq 6000 system (Novogene Co), obtaining a minimum of 200 GB raw data for each
849 library.

850

851 ***snRNA-seq analysis***

852 The demultiplexed FASTQ files were mapped to the GRCm38 genome reference using Cell
853 Ranger (version 7.1.0) with the default settings. The transcriptomic analysis was performed
854 using a Python package called SCANPY⁹⁶. Raw gene expression matrices from 6 snRNA-seq
855 libraries (each library was derived from two animals) were combined for analysis. For quality
856 control, the following criteria was used to exclude low-quality cells or outliers: $n_genes >$
857 6500 or < 700 , $percent_mito > 5\%$, and $n_counts > 40,000$. Genes detected in less than 8 cells
858 were removed³⁷. Cells were normalized using *scanpy.pp.normalize_per_cell* with default
859 setting, followed by log-transformation.

860
861 After quality control, highly variable genes (HVGs) were identified using
862 *scanpy.pp.highly_variable_genes* with default setting. Harmony³⁶ was employed for batch
863 correction. The top 40 principal components (PCs) were used to compute a nearest-neighbor
864 graph on the cells using *scanpy.pp.pca* function. Leiden algorithm⁹⁷ was applied to do
865 clustering with default setting and the graph was finally embedded in 2D via the Uniform
866 Manifold Approximation and Projection (UMAP) algorithm⁹⁸. Canonical marker genes
867 which were reported in previous studies³⁷ were used for annotation. Doublets were identified
868 using Scrublet³⁵. Clusters that expressed markers of more than two classes or contained more
869 than 50% doublets were discarded.

870
871 To further identify types in each class, this combined gene expression matrix was divided
872 into 3 matrices: glutamatergic neurons, GABAergic neurons and non-neuronal cells. The raw
873 matrix of glutamatergic neurons was further processed for highly variable gene selection,
874 batch correction, dimensionality reduction and clustering as described above and visualized
875 by UMAP. Previously reported type-specific markers³⁷ were used for type annotation of
876 glutamatergic neurons.

877
878 Differential expression analysis was performed to assess the transcriptomic alterations
879 between WT and *Cdkl5* KO mouse V1, and to identify markers in each subclass or type.
880 Differential expression analysis in this study was achieved using
881 *scanpy.tl.rank_genes_groups* function in the SCANPY package. Differentially expressed
882 genes were defined as: adjusted P value < 0.05 and a log2 fold change > 0.25 or < -0.25 .

883
884 Enrichment for activity-dependent genes in visual cortex⁹⁹ was calculated using the R
885 package GeneOverlap. The lists of DEGs for each cell type were tested, utilizing all genes
886 existing in snRNA seq from this study as the background. *P* values from Fisher exact
887 test were reported.

888 ***Fluorescent in situ hybridization (FISH)***

890 WT and *Cdkl5* KO mice (8-week-old) were euthanized and perfused as described. The brains
891 were removed and fixed in 4% PFA for 24hr at 4 °C, followed by sucrose gradient until
892 dehydration. Mouse V1 tissues were dissected under microscope and embedded in optimal
893 cutting temperature compound (OCT, Tissue-Tek), and frozen at -80°C. The V1 tissues were
894 sectioned at 20 μm with a cryostat (Epreidia Cryostar NX70 Cryostat). The sections were
895 fixed with 4% PFA for 10 min, washed 3 times with PBS and dehydrated using 70% ethanol.
896 The sections were permeabilized by 8% SDS in PBS for 15 min at room temperature. The
897 sections were then labelled according to the manufacturer's protocol¹⁰⁰ (Molecular
898 Instruments). DAPI was stained before imaging. Probes for *Fos* and *Arc* were commercially
899 designed by the manufacturer (Molecular Instruments). Probe for *Homer1* and *Camk2a* were
900 custom designed and the target sequences are listed below:

901 Homer1-1
902 GGCTATCAGCCCATTTGGCCAAACTTTTGAGATGTTTTAGTAAATGTCATG
903 Homer1-2
904 GCCGAGCAGCTTCCTTAAATTCCTGAAACTTTTCTGCGAATTTTGAAAGA
905 Homer1-3 GCTGAAGATAGGTTGCTCCCC
906 Homer1-4 GGTGTGATGGTGTCTATTTATTATTGCCTTTGAGCCATCTAAACTG
907 Homer1-5 AAGGGGTACTGGTCAGCTCC
908 Camk2a-1 CCACAGCGTGAGAAAGAGCAGCAT
909 Camk2a-2 TTCCCCAGGGCCTCTGGTTCAA
910 Camk2a-3 ATCTGCCATTTGCCGTCCCTGC

911
912 FISH assay on rat primary hippocampal neurons and iNeurons were performed with
913 ViewRNA Fos probe following manufacturer's protocol (Rat: Catalog number: VX-06,
914 Assay ID: VC1-11292-VCP; Human: Catalog number: VX-01, Assay ID: VA1-11504-VC;
915 Thermo Fisher Scientific).

916
917 Leica SP8 confocal microscope with a 40 \times , NA 0.85 objective (SBS core lab, CUHK) was
918 used for imaging. V1 cortical areas were imaged with optical sectioning of 0.5 μ m and 15
919 optical sections. Channels were imaged sequentially to avoid any optical crosstalk. The
920 number and volume of puncta within cells were quantified using the Imaris reconstruction
921 software (v.9.0, Bitplane).

922
923 ***Epitope-preserving Magnified Analysis of Proteome (eMAP), imaging and analysis***
924 We performed eMAP as previously described^{101,102}. Mice under anesthesia were perfused
925 with PBS followed by 4% paraformaldehyde. Brain tissues were collected and post-fixed in 4%
926 paraformaldehyde overnight at 4 $^{\circ}$ C. Brain tissues were then embedded in MAP solution (30%
927 acrylamide, 10% sodium acrylate, 0.1% bisacrylamide, and 0.03% VA-044 in PBS) under
928 hypoxic conditions. The embedded samples were then immersed in hydration solution (0.02%
929 sodium azide in PBS) and sectioned at 60 μ m using a Leica VT1000S vibratome. Lipid was
930 removed by incubation in clearing solution (6% SDS, 0.1 M phosphate buffer, 50 mM
931 sodium sulfite, 0.02% sodium azide in deionized water [pH 7.4]) for 4 hours at 37 $^{\circ}$ C. Samples
932 were then washed with PBST (0.1% Triton X-100 and 0.02% sodium azide in PBS) and
933 stained with primary anti-GFP (A10262, Invitrogen) antibody diluted in PBST overnight at
934 37 $^{\circ}$ C. After washing with PBST, samples were incubated with secondary antibodies diluted in
935 PBST overnight at 37 $^{\circ}$ C and then washed again with PBST. The samples were expanded and
936 mounted in 0.01 \times PBS immediately before imaging. Approximately 3 \times total linear expansion
937 was achieved, and imaging was performed under a Leica SP8 confocal microscope using a
938 20X lens with a 0.75 numerical aperture or 63X water immersion lens with a 1.2 numerical
939 aperture. For dendritic spine morphology analysis, FIJI (version 2.14) was used to measure
940 head diameter (D_{head}), neck diameter (D_{neck}), and the length (L_{length}) of dendritic spines
941 according to dendritic spine classification criteria previously described¹⁰³.

942
943 ***Site-directed mutagenesis***
944 Wildtype sequences of ELAVL 2 to 4 were directly cut out by corresponding restriction
945 enzymes and ligated to in-frame EGFP-C vectors. Then, by using them as templates, SE
946 mutants of Elavls 2 to 4 were built using traditional Primer Extension Mutagenesis with two-
947 stage nested PCR¹⁰⁴. While SA mutants were built using one-stage PCR and Dpn1 digestion
948 method¹⁰⁵.

949 Addgene plasmids carrying wild-type sequences of ELAVL 2 to 4:
950 ELAVL 2: pENTRY4_HuB (65752);

951 ELAVL 3: pENTRY4_HuC (65753);
952 ELAVL 4: pENTRY4_HuD (65754).
953 Primers for SE mutants:
954 ELAVL2:
955 (first-stage PCR1) gcccgaattcggatggaacacaactgtcta
956 atctctgatagaagcttcaactgggcgagcata
957 (first-stage PCR2) tatgctcgccaagtgaagcttctatcagagat
958 ggtacctcgagaggcttgcgtttgtttgt
959 (second-stage PCR) gcccgaattcggatggaacacaactgtcta
960 ggtacctcgagaggcttgcgtttgtttgt
961 ELAVL 3:
962 (first-stage PCR1) gcccgaattcggatggtcactcagatactgggg
963 ccggatggatgcttcaactgggtctggc
964 (first-stage PCR2) gccagaccagtgaagcatccatccgg
965 ggtacctcgagacgcttgcgtttgtgctgg
966 (second-stage PCR) gcccgaattcggatggtcactcagatactgggg
967 ggtacctcgagacgcttgcgtttgtgctgg
968 ELAVL 4:
969 (first-stage PCR1) accgagatctctatggtatgataattagcacc
970 ccctgattgaggcctcgctcggacgggc
971 (first-stage PCR2) gcccgtccgagcaggcctcaatcaggg
972 taccgtcactggactgtgggcttgggt
973 (second-stage PCR) gcccgtccgagcaggcctcaatcaggg
974 taccgtcactggactgtgggcttgggt
975
976 Primers for SA mutants:
977 ELAVL 2: cctatgctcgccaagtgcagcttctatcagagat
978 atctctgatagaagctgcacttgggcgagcatagg
979 ELAVL 3: atgccagaccagtgcagcatccatccgg
980 ccggatggatgctcactgggtctggcat
981 ELAVL 4: tgcccgtccgagcgtcctcaatcag
982 Ctgattgaggcagcgtcggacgggca
983

984 ***LLPhyScore algorithm***

985 The algorithm computed a composite LLPS_score for each entry by integrating eight distinct
986 biophysical features derived from PDB statistical potentials, including solvent accessibility
987 and pi-pi interaction frequencies. We subsequently constructed a global rank-ordered
988 distribution curve by sorting all sequences by their predicted scores. This framework allowed
989 for a quantitative, comparative assessment of the ELAVL family's biophysical driving forces
990 relative to both established high-confidence scaffolds and the general baseline of the
991 proteome.

993 ***Cell line culture, transfection and drug treatment***

994 The primary hippocampal neurons were prepared from embryonic day 18.5 rat embryos.
995 Hippocampal neurons (1×10^5) were plated on 10 μ g/ml poly-D-lysine (Sigma Aldrich)
996 coated 18 mm coverslips in 12-well plates, fed with Neurobasal medium (21103-049, Gibco)
997 supplemented with 2% B27 (17504-044, Gibco) and 1% GlutaMAX (35050-061, Gibco). We
998 performed calcium phosphate transfection on div 11 and fixed the neuron for immunostaining
999 following previously described protocol on div 17¹⁰⁶. The HEK 293T and HT22 cells were
1000 grown in Dulbecco's Modified Eagles Medium (DMEM) supplemented with 10% of fetal

1001 bovine serum and 1% of penicillin/streptomycin solution up to 40 passages. We used the
1002 general PEI transfection protocol by adding 0.4 μg DNA/coverslip, transfect overnight and
1003 perform immunostaining. For Actinomycin D treatment, we replenish the iNeurons with
1004 neurobasal medium containing 2 $\mu\text{g}/\text{mL}$ Actinomycin D at different time point, and fixed
1005 them together for FISH assay.

1006

1007

1008 *iPSC culture*

1009 Human iPSC lines OR00005 (p.R550* mutant allele clone) and OR00006 (WT allele clone)
1010 were purchased from Coriell Institute. The two lines were reprogrammed from a
1011 heterozygous CDD female patient carrying a pathogenic variant 1648C>T (p.R550*) of
1012 CDKL5 in one allele as well as a WT allele. To generate adenine base editor (ABE)-
1013 corrected iPSCs, we electroporated 5 μg ABEmax plasmid with a guide RNA to correct the
1014 mutation using Human Stem Cell Nucleofactor 1 (Lonza, VPH-5012) according to the
1015 manufacturer's protocols. ABE-corrected iPSC clones were selected with puromycin and
1016 confirmed through sanger sequencing. iPSCs were cultured in Essential 8 (E8) Medium
1017 (Thermo Fisher Scientific, A1517001) on 6-well cell culture dishes (SPL, 30006) coated with
1018 Geltrex (Thermo Fisher Scientific, A1414402) diluted 1:100 in DMEM/F-12 (Thermo Fisher
1019 Scientific, 11330032). E8 medium was daily replenished. When iPSC colonies demonstrated
1020 mature morphology, the iPSCs were either clump passaged with EDTA (Thermo Fisher
1021 Scientific, 25300054) for routine maintenance or differentiation into cortical neurons. For
1022 clump passaging with EDTA, iPSCs were washed with Dulbecco's PBS (DPBS; Millipore
1023 Sigma, D8537) and then incubated with EDTA for 5–7 min at 37°C; the EDTA solution was
1024 then aspirated and replaced with E8; iPSC colonies were then gently detached and
1025 resuspended gently and centrifuged at 300 g for 3 min. Then the supernatant was discarded,
1026 and cell pellets were resuspended with E8 + Y-27632 (Sigma Aldrich, Y0503) and passaged
1027 at 1:10–1:40 dilutions in E8 + Y-27632, with Y-27632 removed the next day.

1028

1029 *Two-dimensional neuron differentiation*

1030 For differentiation of iPSCs into cortical neurons, published protocols were followed with
1031 minor modifications¹⁰⁷. iPSCs were plated on 6-well Geltrex-coated plates and suspended
1032 lentivirus with rtTA and Ngn2-GFP-puro vectors 2 hours later in E8 medium containing 10
1033 μM Y-27632 and infected the iPSCs for 24 hours. After the colonies demonstrated mature
1034 morphology (Day 0), the culture medium was replaced with N2 medium (DMEM/F-12, 1 \times
1035 N2 and 1 \times NEAA; Thermo Fisher Scientific) containing 2 $\mu\text{g}/\text{mL}$ doxycycline (Sigma
1036 Aldrich). On day 1, the culture medium was replaced with N2 medium containing 2 $\mu\text{g}/\text{mL}$
1037 doxycycline and 1 $\mu\text{g}/\text{mL}$ puromycin (Thermo Fisher Scientific, A1113803). On day 3, the
1038 induced cells were dissociated with Accutase (Thermo Fisher Scientific, A1110501) and
1039 plated them onto 6-well PDL/laminin coated plates at 1.0×10^6 cells per well or 24-well
1040 plates with coverslips at 5×10^4 cells per coverslip in B27 medium (Neurobasal medium, 1 \times
1041 B27, 1 \times GlutaMAX and 0.2 $\mu\text{g}/\text{mL}$ laminin, Thermo Fisher Scientific) containing 2 $\mu\text{g}/\text{mL}$
1042 doxycycline, 1 $\mu\text{g}/\text{mL}$ puromycin. For further experiments, from day 7 until day 28, half of
1043 the medium was removed every 4 days and was replaced with B27 medium containing 0.5
1044 $\mu\text{g}/\text{mL}$ doxycycline, 10 $\mu\text{g}/\text{mL}$ BDNF and 10 $\mu\text{g}/\text{mL}$ GDNF.

1045

1046 *Immunocytochemistry*

1047 Cells grown on coverslips or chamber slides were fixed with 4% paraformaldehyde (Sigma,
1048 F8775) for 15 min at room temperature. Then the cells were permeabilized with 0.1% Triton
1049 X-100 in DPBS for 5 min at RT and blocked with 1% BSA in DPBS for 20 min. Primary
1050 antibodies were incubated with the cells overnight at 4°C. The following primary antibodies

1051 were used: anti-Elavl2 (Proteintech, 14008-1), anti-Elavl3 (Proteintech, 55047-1), anti-Elavl4
1052 (Santa Cruz, sc-48421 and sc-28299), anti-GFP (Invitrogen, A10262), anti-TIA1 (Santa Cruz,
1053 sc-166247), anti-GW182 (Santa Cruz, sc-56314). After washing three times in DPBS, the
1054 cells were incubated with secondary antibodies and DAPI for 1 hr at room temperature. The
1055 following secondary antibodies were used: Alexa Fluor 488 (Invitrogen, A32931), Alexa
1056 Fluor 555 (Invitrogen, A32732), Alexa Fluor 568 (Invitrogen, A21124), Alexa Fluor 594
1057 (Invitrogen, A32742), Alexa Fluor 647 (Invitrogen, A32728, A32733), STAR Orange
1058 (Abberior, STORANGE-1001, STORANGE-1002) and STAR Red (Abberior, STRED-1001,
1059 STRED-1002). After washing for 3 times, the samples were mounted with anti-fade
1060 mounting medium.

1061
1062 Confocal images were acquired using Leica SP8 microscope with 63x objective, Z-series
1063 images were collected using z-serial scanning mode (20 optical sections at 0.3 μm steps).
1064 STED images were acquired using abberior STED microscopy system at 50 nm resolution, z-
1065 series images were collected using z-serial scanning mode (100 optical sections at 75nm per
1066 step).

1067 1068 ***Quantification of puncta number, volume and fraction distribution***

1069 The number and volume of puncta within cells were quantified using the Imaris
1070 reconstruction software (v.9.0, Bitplane). 3D reconstruction was performed on high-
1071 resolution confocal/STED images. The border of cells and nucleus was determined by surface
1072 module in the software, rendering with 0.1- μm smoothing, and disconnected processes were
1073 merged with the cell body to create a single surface. Then the spots module was used to
1074 measure the number and volume of the fluorescence puncta. The puncta within cells were
1075 limited by distance between puncta and cell surface/Nucleus surface. The fraction
1076 distribution analysis was done by fraction fining puncta within each cell by their volume,
1077 following by non-linear regression.

1078 1079 ***Protein expression and purification***

1080 Human *ELAVL3* (GenBank: NM_001420.4) gene was cloned into a modified pET32a vector
1081 with an N-terminal Trx-His₆-tag. Full-length ELAVL3 was expressed in *Escherichia*
1082 *coli* BL21 (DE3) host cells at 37°C for 4 hr induced by 0.2 mM isopropyl- β -D-
1083 thiogalactoside (IPTG). Cells were harvested and resuspended in buffer containing 50 mM
1084 Tris, pH 8.0, 1 M NaCl, 5% Glycerol, 2 mM β -ME and 10 mM imidazole, and then lysed by
1085 high pressure homogenizer at 4°C. After centrifugation at 18,000 rpm for 20 min, the
1086 supernatants were loaded onto the Ni²⁺-NTA agarose affinity column and eluted with the
1087 buffer containing 50 mM Tris, pH 8.0, 1 M NaCl and 500 mM imidazole, and then purified
1088 by a size-exclusion chromatography in the buffer containing 50 mM Tris, pH 8.0, 1 M NaCl,
1089 5% Glycerol, 1mM EDTA and 1 mM DTT.

1090 1091 ***Protein labeling with fluorophore***

1092 Purified ELAVL3 proteins (~5 mg/mL) were dissolved in the buffer containing 300 mM
1093 NaCl, 100 mM NaHCO₃, pH 8.3, 4 mM β -ME. Cy3 NHS ester (AAT Bioquest) was
1094 dissolved in DMSO and incubated with the corresponding protein (molar ratio ~1:1) at room
1095 temperate for 1 hr. The labeling reaction was quenched by the buffer of 200 mM Tris, pH 8.2,
1096 and the labeled protein was purified with a HiTrap desalting column with the buffer
1097 containing 50 mM Tris, pH 8.0, 1 M NaCl , 5% Glycerol, 1mM EDTA and
1098 1 mM DTT. Fluorescence labeling efficiency was determined by Nanodrop 2000 (Thermo
1099 Fisher).

1100

1101 ***In vitro phase separation assay***

1102 The stock ELAVL3 protein was centrifuged at 16,873 g for 10 min at 4°C to remove any
1103 precipitations and diluted to designed concentrations and buffer conditions. Subsequently, all
1104 the samples were placed on ice before phase separation assay. For microscope-based assays,
1105 each sample was injected into a home-made chamber for fluorescence imaging (Leica TCS
1106 SP8).

1107

1108 ***Fluorescence recovery after photo-bleaching assay***

1109 For FRAP of ELAVL3 SA and SE overexpressed HEK 293T cells, a circular ROI was
1110 bleached by 488 nm laser beam at 37%. The photobleaching was acquired with 50 cycles of
1111 488 nm laser at 10% power and imaging every 0.5 s for 5 min after bleaching. The
1112 fluorescence intensity of the bleached area was normalized to the intensity of the same area
1113 before bleaching. The recovery curves were corrected with the region without photobleaching
1114 in the same frames.

1115

1116 For Cy3-labeled protein droplets, ROI was bleached by a 561 nm laser beam at room
1117 temperature. A dwell time of 1.2 s and 100% of laser power was used during bleaching.
1118 Fluorescence recovery was monitored for 300 s at 5 s intervals. For each experiment, the
1119 fluorescence intensity of a neighboring droplet with similar size to the bleached one was also
1120 recorded for intensity correction. Background intensity was subtracted before data analysis.
1121 The pre-bleaching ROI intensity was normalized to 100%.

1122

1123 ***Co-Immunoprecipitation***

1124 Protein extraction was performed in HEK 293T cells using a NP40 buffer (50 mM Tris-HCl
1125 buffer (pH 7.4), 150 mM NaCl, 2 mM MgCl₂, 1 mM EDTA, 0.5% (v/v) NP40, 1 mM DTT
1126 and complete EDTA-free protease inhibitor cocktail). Pre-clearing of protein extract was
1127 performed by 30 minutes R/T incubation with Protein A magnetic beads (Life Technologies).

1128 Pre-cleared extract was incubated with 2 μg of GW182 antibody (sc-56314; Santa Cruz
1129 Biotechnology) for O/N at 4 °C, then performed immunoprecipitation with Protein A
1130 magnetic beads by 30 minutes R/T incubation. Samples were washed 5 times using NP40
1131 buffer and protein complex were released by resuspending the beads in 1x sample buffer
1132 supplemented with 0.1M DTT and incubated at 95°C for 5-7 min.

1133

1134 ***Electrophoresis Mobility Shift Assay (EMSA)***

1135 nELAVL SE and SA mutants were cloned and overexpressed in E.coli. Proteins were
1136 purified by Gene Universal Inc., (Chuzhou, Anhui). Fos-Cy5 au-rich RNA oligos (sequence:
1137 AUAUUUAUAUUUUUAUUUUUAUUUUUUU) was synthesized by Techdragen. The
1138 binding buffer for EMSA consisted of 60 mM KCl, 300 mM NaCl, 2 mM MgCl₂, 20 mM
1139 HEPES (pH 8.0) 1 mM EDTA, 1 mM DTT, 10 % Glycerol, 0.5 mg/mL of tRNA, and 2 fmol
1140 of Fos-Cy5 RNA per reaction. Reactions were equilibrated for 1 h at room temperature
1141 before loading on a Tris-glycine gel (to minimize complex dissociation), running 45 mins at
1142 100 V. All gel shifts were done at least three times. Bands were quantified using ImageJ.
1143 Fraction bounds were calculated by plotting the ratio of RNA-protein complex against total
1144 RNA. Lines were obtained by nonlinear regression.

1145

1146 ***Puromycin Proximity Ligation Assay (Puro-PLA)***

1147 The Puro-PLA were performed on rat primary hippocampal neurons expressed with
1148 ELAVL3-SE/SA probing Fos protein and puromycin with kit (Duolink® In Situ Red

1149 Starter Kit Mouse/Rabbit, catalog number: DUO92101, Sigma Aldrich) following
1150 manufacturer's instructions.

1151

1152 ***Craniotomy and AAV injection***

1153 6-week-old mice were anesthetized with isoflurane mixed with air (3% for induction, 2% for
1154 surgery) and placed on a stereotaxic apparatus (RWD Instruments). A 38 °C heating pad was
1155 used for maintaining animal body temperature. Ophthalmic ointment (Bausch & Lomb corner
1156 gel) was applied to the eyes for eye lubrication. Ethanol and betadine swabs were used to
1157 sterilize the skin above the skull before making an incision. A ~4 mm craniotomy window
1158 was made over the left V1 (center coordinates were 3.2 mm ML and 1 mm AP relative to
1159 lambda) by a dental drill as described previously¹⁰⁸. A glass pipette (RWD Instruments) was
1160 pulled to a fine tip by a puller (PC-100, Narishige), and filled with mineral oil in the whole
1161 pipette and AAV in the front tip. The filled glass pipette was lowered into the V1. At a depth
1162 of 0.1-0.2 mm below the dura, virus was injected slowly (120nl in 5 min) into V1 using a
1163 microinjector (R480 Nanoliter injection pump, RWD Instruments). After the injection,
1164 pipette was kept for 5 minutes before being withdrawn to prevent the backflow of virus. A
1165 two-layer glass window was made by sticking a 3 mm and 5 mm-diameter cover glass (#1
1166 thickness, Warner Instruments) using UV sensitive optical adhesive. The glued glass window
1167 was placed under slight downward pressure on the exposed brain. The 5 mm was attached to
1168 the skull and the 3 mm was fitted into the craniotomy. A tissue-friendly adhesive (3M
1169 Vetbond) was applied to seal around the surrounding skull. A custom-made stainless steel
1170 head plate was attached to the skull with dental adhesive resin cement. Dental cement was
1171 used to seal the rest of the exposed skull. Two-photon imaging was conducted 2 weeks after
1172 craniotomy window implantation.

1173

1174 ***Viral vectors***

1175 For *in vivo* calcium imaging, rAAV-hSyn-GCaMp6f-WPRE-hGH-polyA (titer:
1176 ~5.7x10¹²vg/ml, BrainVTA Co.,Ltd) was used. For sparse labeling of neurons for eMAP, a
1177 mixture of diluted pENN.AAV.CamKII 0.4.Cre.SV40 (titer: 1.8x10¹³vg/ml, Addgene:
1178 105558, 1:10000-20000 dilution in PBS) and cre-dependent EGFP virus (titer: 1x10¹³ vg/ml,
1179 Addgene: 51502) were used. nELAVL-WT AAV was generated with a mix (1:1:1) of
1180 ELAVL2-WT, ELAVL3-WT and ELAVL4-WT plasmid (titer: 2.45x10¹³vg/ml, Vigene
1181 Biosciences, Inc.). nELAVLs-SE AAV was generated with a mix (1:1:1) of ELAVL2-S119E,
1182 ELAVL3-S119E and ELAVL4-S131E plasmid (titer: 6.60x10¹³vg/ml, Vigene Biosciences,
1183 Inc.). nELAVLs-SA virus was generated with a mix (1:1:1) of ELAVL2-E119A, ELAVL3-
1184 E119A and ELAVL4-E131A plasmid (titer: 8.02x10¹³vg/ml, Vigene Biosciences, Inc.).

1185

1186 ***Two-photon in vivo imaging with visual stimuli***

1187 The Psychophysics Toolbox in MATLAB was used to generate drifting grating stimuli and
1188 natural scene^{109,110}. For each stimuli trial, there was a 3s blank period (gray at mean
1189 luminance) followed by a 1s drifting sinusoidal grating (mean luminance: ~50 lx) with three
1190 different spatial frequencies (0.08, 0.04 and 0.02 cycles per degree) at temporal frequency of
1191 2 Hz followed a 4s blank period with 4s natural scene. Eight drifting directions were
1192 separated by 45 degrees, and ten trials were displayed. An LCD monitor (21.5-inch, 75 Hz
1193 refresh rate) was placed 18 cm centered in front of the mouse's eyes to display the stimuli.
1194 The monitor covered a field of view of ~106 degrees horizontal and ~58 degrees vertical.
1195 Mice were head-fixed, and the left V1 was imaged by a two-photon microscope (Scientifica,
1196 U.K.) with a resonant scanning module controlled by ScanImage built-in Matlab software.
1197 The Coherent Discovery laser was used at 920 nm for excitation through a Nikon water
1198 immersion objective (16X, N.A. = 0.8, working distance: 3.0 mm). The power was less than

1199 100 mW for all imaging. The signal was detected by a photomultiplier with bandwidth of
1200 480-560nm. Images were acquired at ~7.5 Hz (30 Hz averaged to 4) over 512x512 pixels of
1201 each view with bidirectional scanning. BNC DAQ (BNC-2110, National Instruments) was
1202 used to synchronize the two-photon microscope recording and visual stimuli display. Mice
1203 were habituated with the imaging set-up for two to three days (30 min daily) before data
1204 collection. Neurons of L2/3 at 100-250 μ m below dura were imaged. To record visually
1205 evoked responses from different eyes, an opaque black card blocker was placed in front of
1206 the eye according to imaging conditions. 3 to 6 fields of view (FOVs) were collected for each
1207 mouse.

1208

1209 ***Image processing and data analysis for two-photon microscopy***

1210 To extract the calcium signal of each neuron at different imaging conditions (i.e., spatial
1211 frequencies 0.02, 0.04 and 0.08cpd, and ways of eye blocking), all images of the same FOV
1212 were imported and analyzed by suite2p (version 0.10.1) at the same time. The parameters of
1213 suite2p were set as follow: tau of 0.7, denoise of 1, diameter of 9, anatomical only of 1,
1214 maximum iterations of 1, frames per second of 7.5 and 191 minimum neuropil pixels. To
1215 confirm the stereotaxic coordinates reliably targeted bV1, we ensured at least 10% of putative
1216 neurons (regions of interest (ROIs)) extracted from each imaging session elicited time-locked,
1217 visually evoked responses from the ipsi eye, similar to other published reports^{60,65}.

1218

1219 The debris-like ROIs were removed manually (“*iscell*” from 1 to 0). The intensities of the
1220 remaining neurons were saved in .mat files for data analysis in MATLAB (version R2021a).
1221 The raw intensities of neurons were adjusted with neuropil signal according to $F_{adj} = F_{raw} -$
1222 $0.7 \times F_{neu}$ ¹¹¹. Normalization of adjusted intensity was done by transforming into modified Z-
1223 score $Z = \frac{F_{adj} - \text{mean of } F_{OFF}}{\text{Standard deviation of } F_{OFF}}$ ⁶⁵, where F_{OFF} is the 1-second adjusted signal in blank
1224 period just before each visual stimulus of that trial. The neuron with more than 20% of trials
1225 (i.e., > 2 trials in drifting grating and > 6 trials in natural scene) with $Z > 2$ at any stimulus,
1226 as well as the trial-average calculated for all time-point, $Z_{trial_avg} > 2$ in that stimulus, was
1227 counted as stimulus-responsive. Tuning curve was obtained by averaging the Z_{trial_avg} in
1228 each grating direction. To analyze the orientation selectivity of grating-responsive neurons,
1229 the response $R(\theta_k)$ of orientation k is calculated by averaging the Z_{trial_avg} of opposite
1230 directions. The orientation selectivity index (OSI) was defined as the norm of $\vec{L} =$
1231 $\frac{\sum_k R(\theta_k) \exp(2i\theta_k)}{\sum_k R(\theta_k)}$ and the preferred orientation was half of the corresponding angle of \vec{L} , where
1232 θ_k was expressed in radian¹¹². The similarity of their signal was calculated as the distance
1233 correlation between their tuning curves for neuron responding to drifting grating stimuli in
1234 any two viewing conditions¹¹³. The confidence interval of mean difference of OSI
1235 distribution between WT and *Cdkl5* KO mice was estimated with bootstrapped distribution
1236 under significantly large sampling (i.e., 9999 times).

1237

1238 Considering that a neuron can contribute to population encoding regardless of their individual
1239 responses to the stimuli, all extracted putative neurons from suite2p were thus included in the
1240 population analysis. To quantify stimulus information encoded in activities of the neural
1241 populations, we measured the performance of a classifier in the prediction of different
1242 grating¹¹⁴. A support vector machine classifier was trained by 5-fold cross-validation¹¹⁵.
1243 Since the number of trials was limited in our study, the trained classifier would tend to overfit
1244 the training set, which could lead to an underestimation of the performance of the classifier
1245 for the validation set. Therefore, during training, the early stop was applied. Then the
1246 classifier’s performance was evaluated by accuracy on the validation set. To evaluate the

1247 binocular matching in the neural population, decoder was trained with contralateral data set
1248 and tested on both contra- and ipsilateral signal.

1249

1250 ***Visual cliff task***

1251 The visual cliff task assessed mice's preference for descending a platform in an open field.
1252 The field consisted of an open field (40 x 40 x 40 cm) with transparent plexiglass floor
1253 positioned on the edge of a laboratory bench: half of the box rested on the tabletop (the “safe”
1254 side), while the other half extended over the floor 80 cm below (the “cliff” side)⁵⁷. Both sides
1255 featured patterns visible through the plexiglass floor, a black and white checkerboard cover
1256 (3.5 x 3.5 cm squares) was placed on the bench top and extended vertically down to the floor,
1257 creating the illusion of a cliff. Prior to each trial, mice were transported to the testing room
1258 and habituated in their home cages for at least 30 minutes. At the start of each trial, a mouse
1259 was placed on a platform (3 cm in height, 5 cm in diameter) at the center of the box, facing
1260 the middle line between the two sides. The side from which the mouse descended was
1261 recorded by a camera. Each mouse underwent 5 trials, and the open field was cleaned
1262 between trials. The percentage of descents from the cliff side was calculated for each mouse.

1263

1264

1265 **References**

1266

- 1267 1 Montini, E. *et al.* Identification and characterization of a novel serine-threonine
1268 kinase gene from the Xp22 region. *Genomics* **51**, 427-433,
1269 doi:10.1006/geno.1998.5391 (1998).
- 1270 2 Kalscheuer, V. M. *et al.* Disruption of the serine/threonine kinase 9 gene causes
1271 severe X-linked infantile spasms and mental retardation. *Am J Hum Genet* **72**, 1401-
1272 1411, doi:10.1086/375538 (2003).
- 1273 3 Olson, H. E. *et al.* Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: Clinical
1274 Review. *Pediatr Neurol* **97**, 18-25, doi:10.1016/j.pediatrneurol.2019.02.015 (2019).
- 1275 4 Leonard, H. *et al.* CDKL5 deficiency disorder: clinical features, diagnosis, and
1276 management. *Lancet Neurol* **21**, 563-576, doi:10.1016/S1474-4422(22)00035-7
1277 (2022).
- 1278 5 Wang, I. T. *et al.* Loss of CDKL5 disrupts kinome profile and event-related potentials
1279 leading to autistic-like phenotypes in mice. *Proc Natl Acad Sci U S A* **109**, 21516-
1280 21521, doi:10.1073/pnas.1216988110 (2012).
- 1281 6 Mazziotti, R. *et al.* Searching for biomarkers of CDKL5 disorder: early-onset visual
1282 impairment in CDKL5 mutant mice. *Hum Mol Genet* **26**, 2290-2298,
1283 doi:10.1093/hmg/ddx119 (2017).
- 1284 7 Sampedro-Castaneda, M. *et al.* Epilepsy-linked kinase CDKL5 phosphorylates
1285 voltage-gated calcium channel Cav2.3, altering inactivation kinetics and neuronal
1286 excitability. *Nat Commun* **14**, 7830, doi:10.1038/s41467-023-43475-w (2023).
- 1287 8 Zhou, A., Han, S. & Zhou, Z. J. Molecular and genetic insights into an infantile
1288 epileptic encephalopathy - CDKL5 disorder. *Front Biol (Beijing)* **12**, 1-6,
1289 doi:10.1007/s11515-016-1438-7 (2017).
- 1290 9 Munoz, I. M. *et al.* Phosphoproteomic screening identifies physiological substrates of
1291 the CDKL5 kinase. *EMBO J* **37**, doi:10.15252/embj.201899559 (2018).
- 1292 10 Baltussen, L. L. *et al.* Chemical genetic identification of CDKL5 substrates reveals its
1293 role in neuronal microtubule dynamics. *EMBO J* **37**, doi:10.15252/embj.201899763
1294 (2018).
- 1295 11 Khanam, T. *et al.* CDKL5 kinase controls transcription-coupled responses to DNA
1296 damage. *EMBO J* **40**, e108271, doi:10.15252/embj.2021108271 (2021).
- 1297 12 Kim, J. Y. *et al.* A kinome-wide screen identifies a CDKL5-SOX9 regulatory axis in
1298 epithelial cell death and kidney injury. *Nat Commun* **11**, 1924, doi:10.1038/s41467-
1299 020-15638-6 (2020).
- 1300 13 Lopes, A. T., Janiv, O., Claxton, S. & Ultanir, S. K. CDKL5's role in microtubule-
1301 based transport and cognitive function. *bioRxiv*, 2024.2008.2028.610038,
1302 doi:10.1101/2024.08.28.610038 (2024).
- 1303 14 De Santis, R. *et al.* Mutant FUS and ELAVL4 (HuD) Aberrant Crosstalk in
1304 Amyotrophic Lateral Sclerosis. *Cell Rep* **27**, 3818-3831 e3815,
1305 doi:10.1016/j.celrep.2019.05.085 (2019).
- 1306 15 Markmiller, S. *et al.* Context-Dependent and Disease-Specific Diversity in Protein
1307 Interactions within Stress Granules. *Cell* **172**, 590-604 e513,
1308 doi:10.1016/j.cell.2017.12.032 (2018).
- 1309 16 Bowles, K. R. *et al.* ELAVL4, splicing, and glutamatergic dysfunction precede
1310 neuron loss in MAPT mutation cerebral organoids. *Cell* **184**, 4547-4563 e4517,
1311 doi:10.1016/j.cell.2021.07.003 (2021).
- 1312 17 Bolognani, F., Contente-Cuomo, T. & Perrone-Bizzozero, N. I. Novel recognition
1313 motifs and biological functions of the RNA-binding protein HuD revealed by

- 1314 genome-wide identification of its targets. *Nucleic Acids Res* **38**, 117-130,
1315 doi:10.1093/nar/gkp863 (2010).
- 1316 18 Colombrita, C., Silani, V. & Ratti, A. ELAV proteins along evolution: back to the
1317 nucleus? *Mol Cell Neurosci* **56**, 447-455, doi:10.1016/j.mcn.2013.02.003 (2013).
- 1318 19 Ip, J. P. K., Mellios, N. & Sur, M. Rett syndrome: insights into genetic, molecular and
1319 circuit mechanisms. *Nat Rev Neurosci* **19**, 368-382, doi:10.1038/s41583-018-0006-3
1320 (2018).
- 1321 20 Banerjee, A. *et al.* Jointly reduced inhibition and excitation underlies circuit-wide
1322 changes in cortical processing in Rett syndrome. *Proc Natl Acad Sci U S A* **113**,
1323 E7287-E7296, doi:10.1073/pnas.1615330113 (2016).
- 1324 21 Demarest, S. T. *et al.* CDKL5 deficiency disorder: Relationship between genotype,
1325 epilepsy, cortical visual impairment, and development. *Epilepsia* **60**, 1733-1742,
1326 doi:10.1111/epi.16285 (2019).
- 1327 22 Goel, A. *et al.* Impaired perceptual learning in a mouse model of Fragile X syndrome
1328 is mediated by parvalbumin neuron dysfunction and is reversible. *Nat Neurosci* **21**,
1329 1404-1411, doi:10.1038/s41593-018-0231-0 (2018).
- 1330 23 Townsend, L. B., Jones, K. A., Dorsett, C. R., Philpot, B. D. & Smith, S. L. Deficits
1331 in higher visual area representations in a mouse model of Angelman syndrome. *J*
1332 *Neurodev Disord* **12**, 28, doi:10.1186/s11689-020-09329-y (2020).
- 1333 24 Galli, J. *et al.* Neurovisual profile in children affected by Angelman syndrome. *Brain*
1334 *Dev* **45**, 117-125, doi:10.1016/j.braindev.2022.10.003 (2023).
- 1335 25 Boggio, E. M. *et al.* Visual impairment in FOXP1-mutated individuals and mice.
1336 *Neuroscience* **324**, 496-508, doi:10.1016/j.neuroscience.2016.03.027 (2016).
- 1337 26 Olson, H. E. *et al.* Cerebral visual impairment in CDKL5 deficiency disorder: vision
1338 as an outcome measure. *Dev Med Child Neurol* **63**, 1308-1315,
1339 doi:10.1111/dmcn.14908 (2021).
- 1340 27 Brock, D. *et al.* Cerebral Visual Impairment in CDKL5 Deficiency Disorder
1341 Correlates With Developmental Achievement. *J Child Neurol* **36**, 974-980,
1342 doi:10.1177/08830738211019284 (2021).
- 1343 28 Lupori, L. *et al.* Site-specific abnormalities in the visual system of a mouse model of
1344 CDKL5 deficiency disorder. *Hum Mol Genet* **28**, 2851-2861,
1345 doi:10.1093/hmg/ddz102 (2019).
- 1346 29 Pizzo, R. *et al.* Lack of Cdk15 Disrupts the Organization of Excitatory and Inhibitory
1347 Synapses and Parvalbumin Interneurons in the Primary Visual Cortex. *Front Cell*
1348 *Neurosci* **10**, 261, doi:10.3389/fncel.2016.00261 (2016).
- 1349 30 Quintiliani, M. *et al.* Cortical Visual Impairment in CDKL5 Deficiency Disorder.
1350 *Front Neurol* **12**, 805745, doi:10.3389/fneur.2021.805745 (2021).
- 1351 31 Eyers, P. A. A new consensus for evaluating CDKL5/STK9-dependent signalling
1352 mechanisms. *EMBO J* **37**, doi:10.15252/embj.2018100848 (2018).
- 1353 32 Mulligan, M. R. & Bicknell, L. S. The molecular genetics of nELAVL in brain
1354 development and disease. *Eur J Hum Genet* **31**, 1209-1217, doi:10.1038/s41431-023-
1355 01456-z (2023).
- 1356 33 Scheckel, C. *et al.* Regulatory consequences of neuronal ELAV-like protein binding
1357 to coding and non-coding RNAs in human brain. *Elife* **5**, doi:10.7554/eLife.10421
1358 (2016).
- 1359 34 Crair, M. C., Gillespie, D. C. & Stryker, M. P. The role of visual experience in the
1360 development of columns in cat visual cortex. *Science* **279**, 566-570,
1361 doi:10.1126/science.279.5350.566 (1998).

- 1362 35 Wolock, S. L., Lopez, R. & Klein, A. M. Scrublet: Computational Identification of
1363 Cell Doublets in Single-Cell Transcriptomic Data. *Cell Syst* **8**, 281-291 e289,
1364 doi:10.1016/j.cels.2018.11.005 (2019).
- 1365 36 Korsunsky, I. *et al.* Fast, sensitive and accurate integration of single-cell data with
1366 Harmony. *Nat Methods* **16**, 1289-1296, doi:10.1038/s41592-019-0619-0 (2019).
- 1367 37 Cheng, S. *et al.* Vision-dependent specification of cell types and function in the
1368 developing cortex. *Cell* **185**, 311-327 e324, doi:10.1016/j.cell.2021.12.022 (2022).
- 1369 38 Kim, E. J. *et al.* Extraction of Distinct Neuronal Cell Types from within a Genetically
1370 Continuous Population. *Neuron* **107**, 274-282 e276,
1371 doi:10.1016/j.neuron.2020.04.018 (2020).
- 1372 39 O'Toole, S. M., Oyibo, H. K. & Keller, G. B. Molecularly targetable cell types in
1373 mouse visual cortex have distinguishable prediction error responses. *Neuron* **111**,
1374 2918-2928 e2918, doi:10.1016/j.neuron.2023.08.015 (2023).
- 1375 40 Jenks, K. R. *et al.* Arc restores juvenile plasticity in adult mouse visual cortex. *Proc*
1376 *Natl Acad Sci U S A* **114**, 9182-9187, doi:10.1073/pnas.1700866114 (2017).
- 1377 41 Brakeman, P. R. *et al.* Homer: a protein that selectively binds metabotropic glutamate
1378 receptors. *Nature* **386**, 284-288, doi:10.1038/386284a0 (1997).
- 1379 42 Barber, C. F., Jorquera, R. A., Melom, J. E. & Littleton, J. T. Postsynaptic regulation
1380 of synaptic plasticity by synaptotagmin 4 requires both C2 domains. *J Cell Biol* **187**,
1381 295-310, doi:10.1083/jcb.200903098 (2009).
- 1382 43 Aiken, J., Buscaglia, G., Bates, E. A. & Moore, J. K. The alpha-Tubulin gene
1383 TUBA1A in Brain Development: A Key Ingredient in the Neuronal Isotype Blend. *J*
1384 *Dev Biol* **5**, doi:10.3390/jdb5030008 (2017).
- 1385 44 Gu, Y. *et al.* Obligatory role for the immediate early gene NARP in critical period
1386 plasticity. *Neuron* **79**, 335-346, doi:10.1016/j.neuron.2013.05.016 (2013).
- 1387 45 Kwapis, J. L. *et al.* Epigenetic regulation of the circadian gene *Per1* contributes to
1388 age-related changes in hippocampal memory. *Nat Commun* **9**, 3323,
1389 doi:10.1038/s41467-018-05868-0 (2018).
- 1390 46 Paradis, S. *et al.* An RNAi-based approach identifies molecules required for
1391 glutamatergic and GABAergic synapse development. *Neuron* **53**, 217-232,
1392 doi:10.1016/j.neuron.2006.12.012 (2007).
- 1393 47 Ban, Y. *et al.* Prickle promotes the formation and maintenance of glutamatergic
1394 synapses by stabilizing the intercellular planar cell polarity complex. *Sci Adv* **7**,
1395 eabh2974, doi:10.1126/sciadv.abh2974 (2021).
- 1396 48 Li, M. *et al.* CDKL5 modulates structural plasticity of excitatory synapses via liquid-
1397 liquid phase separation. *bioRxiv*, 2025.2003.2016.643581,
1398 doi:10.1101/2025.03.16.643581 (2025).
- 1399 49 Cai, H., Vernon, R. M. & Forman-Kay, J. D. An interpretable machine learning
1400 algorithm to predict disordered protein phase separation based on biophysical
1401 interactions. *bioRxiv*, 2022.2007.2006.499043, doi:10.1101/2022.07.06.499043
1402 (2022).
- 1403 50 Li, J. *et al.* Post-translational modifications in liquid-liquid phase separation: a
1404 comprehensive review. *Mol Biomed* **3**, 13, doi:10.1186/s43556-022-00075-2 (2022).
- 1405 51 Ripin, N. & Parker, R. Formation, function, and pathology of RNP granules. *Cell* **186**,
1406 4737-4756, doi:10.1016/j.cell.2023.09.006 (2023).
- 1407 52 Youn, J. Y. *et al.* Properties of Stress Granule and P-Body Proteomes. *Mol Cell* **76**,
1408 286-294, doi:10.1016/j.molcel.2019.09.014 (2019).
- 1409 53 Hubstenberger, A. *et al.* P-Body Purification Reveals the Condensation of Repressed
1410 mRNA Regulons. *Mol Cell* **68**, 144-157 e145, doi:10.1016/j.molcel.2017.09.003
1411 (2017).


- 1412 54 Wilbertz, J. H. *et al.* Single-Molecule Imaging of mRNA Localization and Regulation
1413 during the Integrated Stress Response. *Mol Cell* **73**, 946-958 e947,
1414 doi:10.1016/j.molcel.2018.12.006 (2019).
- 1415 55 Kodali, S. *et al.* RNA sequestration in P-bodies sustains myeloid leukaemia. *Nat Cell*
1416 *Biol* **26**, 1745-1758, doi:10.1038/s41556-024-01489-6 (2024).
- 1417 56 Sato, K. & Kotani, T. Visualizing the translational activation of a particular mRNA in
1418 zebrafish embryos using in situ hybridization and proximity ligation assay. *STAR*
1419 *Protoc* **5**, 102951, doi:10.1016/j.xpro.2024.102951 (2024).
- 1420 57 De Jesus-Cortes, H. *et al.* Using the visual cliff and pole descent assays to detect
1421 binocular disruption in mice. *bioRxiv*, doi:10.1101/2023.05.29.542767 (2024).
- 1422 58 Boone, H. C. *et al.* Natural binocular depth discrimination behavior in mice explained
1423 by visual cortical activity. *Curr Biol* **31**, 2191-2198 e2193,
1424 doi:10.1016/j.cub.2021.02.031 (2021).
- 1425 59 Chen, T. W. *et al.* Ultrasensitive fluorescent proteins for imaging neuronal activity.
1426 *Nature* **499**, 295-300, doi:10.1038/nature12354 (2013).
- 1427 60 Tan, L., Tring, E., Ringach, D. L., Zipursky, S. L. & Trachtenberg, J. T. Vision
1428 Changes the Cellular Composition of Binocular Circuitry during the Critical Period.
1429 *Neuron* **108**, 735-747 e736, doi:10.1016/j.neuron.2020.09.022 (2020).
- 1430 61 Chang, J. T., Whitney, D. & Fitzpatrick, D. Experience-Dependent Reorganization
1431 Drives Development of a Binocularly Unified Cortical Representation of Orientation.
1432 *Neuron* **107**, 338-350 e335, doi:10.1016/j.neuron.2020.04.022 (2020).
- 1433 62 Tan, L. M., Ringach, D. L. & Trachtenberg, J. T. The Development of Receptive
1434 Field Tuning Properties in Mouse Binocular Primary Visual Cortex. *Journal of*
1435 *Neuroscience* **42**, doi:10.1523/Jneurosci.1702-21.2022 (2022).
- 1436 63 Espinosa, J. S. & Stryker, M. P. Development and plasticity of the primary visual
1437 cortex. *Neuron* **75**, 230-249, doi:10.1016/j.neuron.2012.06.009 (2012).
- 1438 64 Wang, B. S., Samaik, R. & Cang, J. Critical period plasticity matches binocular
1439 orientation preference in the visual cortex. *Neuron* **65**, 246-256,
1440 doi:10.1016/j.neuron.2010.01.002 (2010).
- 1441 65 Jenks, K. R. & Shepherd, J. D. Experience-Dependent Development and Maintenance
1442 of Binocular Neurons in the Mouse Visual Cortex. *Cell Rep* **30**, 1982-1994 e1984,
1443 doi:10.1016/j.celrep.2020.01.031 (2020).
- 1444 66 Smith, S. L. & Trachtenberg, J. T. Experience-dependent binocular competition in the
1445 visual cortex begins at eye opening. *Nat Neurosci* **10**, 370-375, doi:10.1038/nn1844
1446 (2007).
- 1447 67 Ukita, J. Causal importance of low-level feature selectivity for generalization in
1448 image recognition. *Neural Netw* **125**, 185-193, doi:10.1016/j.neunet.2020.02.009
1449 (2020).
- 1450 68 Sun, Y. J., Espinosa, J. S., Hoseini, M. S. & Stryker, M. P. Experience-dependent
1451 structural plasticity at pre- and postsynaptic sites of layer 2/3 cells in developing
1452 visual cortex. *Proc Natl Acad Sci U S A* **116**, 21812-21820,
1453 doi:10.1073/pnas.1914661116 (2019).
- 1454 69 Song, J. Molecular Mechanisms of Phase Separation and Amyloidosis of ALS/FTD-
1455 linked FUS and TDP-43. *Aging Dis* **15**, 2084-2112, doi:10.14336/AD.2023.1118
1456 (2024).
- 1457 70 Liu, N., Guo, Y., Ning, S. & Duan, M. Phosphorylation regulates the binding of
1458 intrinsically disordered proteins via a flexible conformation selection mechanism.
1459 *Commun Chem* **3**, 123, doi:10.1038/s42004-020-00370-5 (2020).
- 1460 71 Maharana, S. *et al.* RNA buffers the phase separation behavior of prion-like RNA
1461 binding proteins. *Science* **360**, 918-921, doi:10.1126/science.aar7366 (2018).

- 1462 72 Di Stefano, B. *et al.* The RNA Helicase DDX6 Controls Cellular Plasticity by
1463 Modulating P-Body Homeostasis. *Cell Stem Cell* **25**, 622-638 e613,
1464 doi:10.1016/j.stem.2019.08.018 (2019).
- 1465 73 Courel, M. *et al.* GC content shapes mRNA storage and decay in human cells. *Elife* **8**,
1466 doi:10.7554/eLife.49708 (2019).
- 1467 74 Marcelo, A., Koppenol, R., de Almeida, L. P., Matos, C. A. & Nobrega, C. Stress
1468 granules, RNA-binding proteins and polyglutamine diseases: too much aggregation?
1469 *Cell Death Dis* **12**, 592, doi:10.1038/s41419-021-03873-8 (2021).
- 1470 75 Sheth, U. & Parker, R. Decapping and decay of messenger RNA occur in cytoplasmic
1471 processing bodies. *Science* **300**, 805-808, doi:10.1126/science.1082320 (2003).
- 1472 76 Dar, S. A. *et al.* Full-length direct RNA sequencing uncovers stress granule-
1473 dependent RNA decay upon cellular stress. *Elife* **13**, doi:10.7554/eLife.96284 (2024).
- 1474 77 Blake, L. A., Watkins, L., Liu, Y., Inoue, T. & Wu, B. A rapid inducible RNA decay
1475 system reveals fast mRNA decay in P-bodies. *Nat Commun* **15**, 2720,
1476 doi:10.1038/s41467-024-46943-z (2024).
- 1477 78 Hallacli, E. *et al.* The Parkinson's disease protein alpha-synuclein is a modulator of
1478 processing bodies and mRNA stability. *Cell* **185**, 2035-2056 e2033,
1479 doi:10.1016/j.cell.2022.05.008 (2022).
- 1480 79 Bentmann, E., Haass, C. & Dormann, D. Stress granules in neurodegeneration--
1481 lessons learnt from TAR DNA binding protein of 43 kDa and fused in sarcoma. *FEBS*
1482 *J* **280**, 4348-4370, doi:10.1111/febs.12287 (2013).
- 1483 80 Wolozin, B. & Ivanov, P. Stress granules and neurodegeneration. *Nat Rev Neurosci*
1484 **20**, 649-666, doi:10.1038/s41583-019-0222-5 (2019).
- 1485 81 Ince-Dunn, G. *et al.* Neuronal Elav-like (Hu) proteins regulate RNA splicing and
1486 abundance to control glutamate levels and neuronal excitability. *Neuron* **75**, 1067-
1487 1080, doi:10.1016/j.neuron.2012.07.009 (2012).
- 1488 82 Akamatsu, W. *et al.* The RNA-binding protein HuD regulates neuronal cell identity
1489 and maturation. *Proc Natl Acad Sci U S A* **102**, 4625-4630,
1490 doi:10.1073/pnas.0407523102 (2005).
- 1491 83 DeBoer, E. M. *et al.* Prenatal deletion of the RNA-binding protein HuD disrupts
1492 postnatal cortical circuit maturation and behavior. *J Neurosci* **34**, 3674-3686,
1493 doi:10.1523/JNEUROSCI.3703-13.2014 (2014).
- 1494 84 Berto, S., Usui, N., Konopka, G. & Fogel, B. L. ELAVL2-regulated transcriptional
1495 and splicing networks in human neurons link neurodevelopment and autism. *Hum*
1496 *Mol Genet* **25**, 2451-2464, doi:10.1093/hmg/ddw110 (2016).
- 1497 85 Zhou, X. *et al.* Integrating de novo and inherited variants in 42,607 autism cases
1498 identifies mutations in new moderate-risk genes. *Nat Genet* **54**, 1305-1319,
1499 doi:10.1038/s41588-022-01148-2 (2022).
- 1500 86 Satterstrom, F. K. *et al.* Large-Scale Exome Sequencing Study Implicates Both
1501 Developmental and Functional Changes in the Neurobiology of Autism. *Cell* **180**,
1502 568-584 e523, doi:10.1016/j.cell.2019.12.036 (2020).
- 1503 87 Rodin, R. E. *et al.* The landscape of somatic mutation in cerebral cortex of autistic
1504 and neurotypical individuals revealed by ultra-deep whole-genome sequencing. *Nat*
1505 *Neurosci* **24**, 176-185, doi:10.1038/s41593-020-00765-6 (2021).
- 1506 88 Jia, X. *et al.* De novo variants in genes regulating stress granule assembly associate
1507 with neurodevelopmental disorders. *Sci Adv* **8**, eabo7112,
1508 doi:10.1126/sciadv.abo7112 (2022).
- 1509 89 Eising, E. *et al.* A set of regulatory genes co-expressed in embryonic human brain is
1510 implicated in disrupted speech development. *Mol Psychiatry* **24**, 1065-1078,
1511 doi:10.1038/s41380-018-0020-x (2019).

- 1512 90 Andrews, S. (Babraham Bioinformatics, Babraham Institute, Cambridge, United
1513 Kingdom, 2010).
- 1514 91 Kim, D., Paggi, J. M., Park, C., Bennett, C. & Salzberg, S. L. Graph-based genome
1515 alignment and genotyping with HISAT2 and HISAT-genotype. *Nat Biotechnol* **37**,
1516 907-915, doi:10.1038/s41587-019-0201-4 (2019).
- 1517 92 Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program
1518 for assigning sequence reads to genomic features. *Bioinformatics* **30**, 923-930,
1519 doi:10.1093/bioinformatics/btt656 (2014).
- 1520 93 Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and
1521 dispersion for RNA-seq data with DESeq2. *Genome Biol* **15**, 550,
1522 doi:10.1186/s13059-014-0550-8 (2014).
- 1523 94 Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for
1524 comparing biological themes among gene clusters. *OMICS* **16**, 284-287,
1525 doi:10.1089/omi.2011.0118 (2012).
- 1526 95 Lau, S. F., Cao, H., Fu, A. K. Y. & Ip, N. Y. Single-nucleus transcriptome analysis
1527 reveals dysregulation of angiogenic endothelial cells and neuroprotective glia in
1528 Alzheimer's disease. *Proc Natl Acad Sci U S A* **117**, 25800-25809,
1529 doi:10.1073/pnas.2008762117 (2020).
- 1530 96 Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene
1531 expression data analysis. *Genome Biol* **19**, 15, doi:10.1186/s13059-017-1382-0 (2018).
- 1532 97 Traag, V. A., Waltman, L. & van Eck, N. J. From Louvain to Leiden: guaranteeing
1533 well-connected communities. *Sci Rep* **9**, 5233, doi:10.1038/s41598-019-41695-z
1534 (2019).
- 1535 98 Becht, E. *et al.* Dimensionality reduction for visualizing single-cell data using UMAP.
1536 *Nat Biotechnol*, doi:10.1038/nbt.4314 (2018).
- 1537 99 Hrvatin, S. *et al.* Single-cell analysis of experience-dependent transcriptomic states in
1538 the mouse visual cortex. *Nat Neurosci* **21**, 120-129, doi:10.1038/s41593-017-0029-5
1539 (2018).
- 1540 100 Choi, H. M., Beck, V. A. & Pierce, N. A. Next-generation in situ hybridization chain
1541 reaction: higher gain, lower cost, greater durability. *ACS Nano* **8**, 4284-4294,
1542 doi:10.1021/nn405717p (2014).
- 1543 101 Ku, T. *et al.* Multiplexed and scalable super-resolution imaging of three-dimensional
1544 protein localization in size-adjustable tissues. *Nat Biotechnol* **34**, 973-981,
1545 doi:10.1038/nbt.3641 (2016).
- 1546 102 Park, J. *et al.* Epitope-preserving magnified analysis of proteome (eMAP). *Sci Adv* **7**,
1547 eabf6589, doi:10.1126/sciadv.abf6589 (2021).
- 1548 103 Zhao, J. *et al.* Specific depletion of the motor protein KIF5B leads to deficits in
1549 dendritic transport, synaptic plasticity and memory. *Elife* **9**, doi:10.7554/eLife.53456
1550 (2020).
- 1551 104 Reikofski, J. & Tao, B. Y. Polymerase chain reaction (PCR) techniques for site-
1552 directed mutagenesis. *Biotechnol Adv* **10**, 535-547, doi:10.1016/0734-9750(92)91451-
1553 j (1992).
- 1554 105 Fisher, C. L. & Pei, G. K. Modification of a PCR-based site-directed mutagenesis
1555 method. *Biotechniques* **23**, 570-571, 574, doi:10.2144/97234bm01 (1997).
- 1556 106 Ip, J. P. *et al.* alpha2-chimaerin controls neuronal migration and functioning of the
1557 cerebral cortex through CRMP-2. *Nat Neurosci* **15**, 39-47, doi:10.1038/nn.2972
1558 (2011).
- 1559 107 Ye, T. *et al.* Efficient manipulation of gene dosage in human iPSCs using
1560 CRISPR/Cas9 nickases. *Commun Biol* **4**, 195, doi:10.1038/s42003-021-01722-0
1561 (2021).

- 1562 108 El-Boustani, S. *et al.* Locally coordinated synaptic plasticity of visual cortex neurons
1563 in vivo. *Science* **360**, 1349-1354, doi:10.1126/science.aao0862 (2018).
- 1564 109 Brainard, D. H. The Psychophysics Toolbox. *Spat Vis* **10**, 433-436 (1997).
- 1565 110 Pelli, D. G. The VideoToolbox software for visual psychophysics: Transforming
1566 numbers into movies. *Spatial Vision* **10**, 437-442, doi:Doi 10.1163/156856897x00366
1567 (1997).
- 1568 111 Stringer, C., Pachitariu, M., Steinmetz, N., Carandini, M. & Harris, K. D. High-
1569 dimensional geometry of population responses in visual cortex. *Nature* **571**, 361-365,
1570 doi:10.1038/s41586-019-1346-5 (2019).
- 1571 112 Mazurek, M., Kager, M. & Van Hooser, S. D. Robust quantification of orientation
1572 selectivity and direction selectivity. *Front Neural Circuits* **8**, 92,
1573 doi:10.3389/fncir.2014.00092 (2014).
- 1574 113 Székely, G. J., Rizzo, M. L. & Bakirov, N. K. Measuring and testing dependence by
1575 correlation of distances. *The Annals of Statistics* **35**, 2769-2794, 2726 (2007).
- 1576 114 Kafashan, M. *et al.* Scaling of sensory information in large neural populations shows
1577 signatures of information-limiting correlations. *Nat Commun* **12**, 473,
1578 doi:10.1038/s41467-020-20722-y (2021).
- 1579 115 Pedregosa, F. *et al.* Scikit-learn: Machine learning in Python. *the Journal of machine*
1580 *Learning research* **12**, 2825-2830 (2011).
- 1581
- 1582
- 1583
- 1584
- 1585
- 1586
- 1587
- 1588
- 1589
- 1590
- 1591
- 1592
- 1593
- 1594
- 1595
- 1596
- 1597
- 1598
- 1599
- 1600
- 1601
- 1602
- 1603
- 1604
- 1605
- 1606
- 1607
- 1608

Fig 1



1609

1610

Figure 1. nELAVLs are phosphorylation substrates of CDKL5.

1611

1612 (A) Workflow of phosphoproteomic screening in WT and *Cdkl5* KO primary visual (V1)

1613 cortices. V1 tissues were harvested for isobaric peptide labelling, followed by peptide

1614 pooling and phosphopeptide enrichment. The samples were then quantitatively identified by

1615 liquid chromatography-tandem mass spectrometry (LC-MS/MS).

1616

1617 (B) Volcano plot showing the \log_2 (fold change) and $-\log_{10}$ (p-value) of each gene comparing

1618 WT and *Cdkl5* KO mice. Differentially expressed phosphopeptides with fold change > 1.2

1619 and < 0.83 are highlighted in pink and blue, respectively. Dashed lines indicate $p < 0.05$ and

1620 a fold change > 1.2 or < 0.83 . Each point represents one peptide, those with the CDKL5

1621 consensus motif (RPXS*A/RPXS*) are labeled with gene name.

1622

1623 (C) Gene Ontology (GO) term enrichment of down-regulated differentially expressed genes

1624 between WT and *Cdkl5* KO mice.

1625

1626 (D) Conserved consensus serine phosphorylation sequence in ELAVL2 (119), ELAVL3 (119)

1627 and ELAVL4 (131) in human, mouse and rat.

1628

1629 (E) Immunoblotting of immunoprecipitates for phosphorylated serine of ELAVL2, ELAVL3

1630 and ELAVL4 in CDKL5-expressing HEK 293T cell. The mutation of serine to alanine at the

1631 RPXS*A motif prevented the phosphorylation.

1632

1633

1633 (F & G) Levels of pS-nELAVLs in visual, frontal and motor cortices were virtually
1634 undetectable in *Cdkl5* KO mice. Visual: n=4 mice, frontal and motor: n=3 mice. Unpaired t-
1635 test (two-tailed).
1636
1637 (H & I) Increased pS-nELAVLs in visual cortex in WT mice after dark environment (16hr)
1638 with 0hr, 1hr and 2hr light induction. n=5 mice. Unpaired t-test (two-tailed). Dot lines
1639 indicate the same batch of experiments. Data are presented as mean \pm SEM, ** p < 0.01. ***
1640 p < 0.001. **** p < 0.0001.

1646 \log_2 (fold change) $> \pm 0.25$ and < -0.25 are highlighted in pink and blue, respectively.
1647 Activity-dependent genes are highlighted in green. The dashed line indicates FDR-adjusted
1648 p-value $< \pm 0.05$ and \log_2 (fold change) $> \pm 0.25$ and < -0.25 .

1649

1650 (B) Hub genes of DEGs between WT and *Cdkl5* KO mouse V1 were identified from PPI
1651 network by maximal clique centrality (MCC) algorithm. Edges represent the protein-protein
1652 associations. The shading from red to yellow depicts MCC scores from high to low.

1653

1654 (C) UMAP plot visualizing annotated subclasses of WT and *Cdkl5* KO mouse V1.

1655

1656 (D) Matrix plot showing activity-dependent DEGs identified between WT and *Cdkl5* KO
1657 mouse V1. 29 overlapped activity-dependent DEGs between bulk and snRNA sequencing are
1658 underlined.

1659

1660 (E) Dot plot showing *Cdkl5* and *nElavls* gene expression across subclasses of WT and *Cdkl5*
1661 KO mouse V1.

1662

1663 (F) Number of DEGs between WT and *Cdkl5* KO mouse V1 in individual cell types of
1664 glutamatergic neurons, genes up- and down-regulated in *Cdkl5* KO compared with WT
1665 shown in pink and blue bars, respectively. DEGs were defined as genes with $|\log_2$ fold
1666 change > 0.25 (light colored bars) or > 0.58 (dark colored bars) and FDR-adjusted p-value $<$
1667 0.05.

1668

1669 (G) Dot plot visualizing enrichment results of activity-dependent genes with DEGs.
1670 Enrichment was calculated separately for DEGs identified in individual cell types of
1671 glutamatergic neurons. Dot size is the number of intersected genes. Color is shaded by $-\log_{10}$
1672 (P value) (one-sided Fisher's exact test). 'ns' indicates P value $\geq \pm 0.05$.

1673

1674 (H) Dot plot visualizing *Homer1*, *Syt4*, *Tuba1a*, *Cdh13*, *Nptx2*, *Per1*, *Arc* and *Prickle1* gene
1675 expression levels in sublayers of Layer 2/3 glutamatergic neurons in WT and *Cdkl5*
1676 KO mouse V1.

1677

1678 (I) FISH images of mRNA expression of *Fos*, *Homer1*, *Arc*, *Camk2a* in WT and *Cdkl5* KO
1679 mouse V1. Scale bars, 20 μ m.

1680

1681 (J) (Top) Bar plot quantifying *Fos*, *Homer1*, *Arc*, *Camk2a* mRNA expression levels. The
1682 quantification of mRNA numbers was normalized to the number of DAPI+ cells per image.
1683 (Bottom) Quantification of *Fos*, *Homer1*, *Arc*, *Camk2a* mRNA punctum volume. *Fos* and
1684 *Homer1*: n=4 mice, *Arc* and *Camk2a*: n=3 mice. Mann-Whitney test (two-tailed). Data are
1685 presented as mean \pm SEM, * p < 0.05. *** p < 0.001. **** p < 0.0001.

1686

1687

1688

1689

1690


1691

1692

1693

1694

Fig 3



1695

1696


1697

1698

1699

1700 volume distribution among neurons. Scale bar, 10 μm and 3 μm for zoomed-in images (right)
1701 of ELAVL3 and nELAVL. WT: n=21 neurons from 3 mice; *Cdkl5* KO: n=27 neurons from 3
1702 mice. Left: Mann-Whitney test (two-tailed); Right: Two-way ANOVA with Sidak's multiple
1703 comparisons test on main effect of WT and *Cdkl5* KO.
1704
1705 (C) Super-resolution STED microscopy of overexpressed WT and SE/SA mutant of ELAVL3
1706 in rat primary hippocampal neurons. Compared to SE, SA mutant showed large-shifted
1707 punctum volume distribution among neurons. Scale bar, 5 μm . n=4 cells from 3 batches of
1708 experiments. Left: One-way ANOVA followed by Turkey's multiple comparisons test; Right:
1709 Two-way ANOVA with Sidak's multiple comparisons test on main effect of SE and SA.
1710
1711 (D) Time-lapse images showing that ELAVL3 droplets fused with each other over time in
1712 ELAVL3-SA-overexpressing HEK 293T cells. Scale bar, 3 μm .
1713
1714 (E) Confocal images showing fluorescence recovery between ELAVL3-SA and -SE puncta.
1715 Bleaching area radius \sim 2.5 μm . Images represent the ELAVL3 puncta before bleaching and
1716 right after bleaching (5s, 40s and 60s). Scale bar, 5 μm
1717
1718 (F) Fluorescence recovery rate of bleached SA puncta was slower than those of bleached
1719 cytoplasm or bleached SE puncta. n=20 (unbleached cytoplasm), 12 (bleached cytoplasm), 24
1720 (bleached SA puncta) and 17 (bleached SE puncta) cells from 3 batches of experiments. Two-
1721 way ANOVA with Sidak's multiple comparisons test.
1722
1723 (G) Purified full length ELAVL3 protein underwent phase separation at indicated
1724 concentrations. ELAVL3 was sparsely labelled by Cy3 fluorophore at 1%. Scale bar, 5 μm .
1725
1726 (H) Time-lapse images showing that ELAVL3 droplets fused with each other over time.
1727 Scale bar, 5 μm .
1728
1729 (I) The number of ELAVL3 droplets decreased when NaCl concentration increased. Scale bar,
1730 5 μm .
1731
1732 (J) Phase separation diagram showing phase separation properties within demonstrated NaCl
1733 concentration and ELAVL3 concentration. The highlighted red dots: phase separation; grey
1734 dots: no phase separation.
1735
1736 (K) Fluorescence recovery analysis showing that ELAVL3 in condensed droplets
1737 dynamically exchanged with those in the dilute phase. Data are presented as mean \pm SEM,
1738 **** p < 0.0001.
1739
1740
1741
1742
1743
1744
1745
1746
1747

Fig 4




1748
1749
1750
1751

Figure 4. CDD patient iPSC-derived neurons forms aberrant nELAVL condensates and altered crosstalk with P-bodies.

1752 (A) An illustration of CDD patient iPSC-derived cortical neurons (iNeurons). iPSCs lines:
1753 R550* = CDKL5 deficient, control = wildtype (WT) and isogenic control = R550* that has
1754 undergone adenine base editing (ABE) to restore CDKL5 expression.
1755
1756 (B & C) CDKL5 expression levels were comparable between control and isogenic control
1757 iNeurons but absent in R550* iNeurons. n=3. One-way ANOVA followed by Tukey's
1758 multiple comparisons test.
1759
1760 (D & E) pS-nELAVLs levels were comparable between control and isogenic control
1761 iNeurons but reduced in R550* iNeurons. Control: n=6, R550*: n=7, isogenic control: n=8.
1762 One-way ANOVA followed by Tukey's multiple comparisons test.
1763
1764 (F & G) STED microscopy showed large-shifted punctum volume distribution of ELAVL3
1765 (green) and nELAVLs (red) in R550* iNeurons, in comparison to control and isogenic
1766 control iNeurons. Scale bar, 5 μ m. n=6 cells from 3 batches of experiments. Left: One-way
1767 ANOVA with Tukey's multiple comparisons test; Right: Two-way ANOVA with Sidak's
1768 multiple comparisons test on main effect of Control, R550* and Iso control; Multiple
1769 comparisons: top: $p < 0.0001$ for Control vs R550*, $p < 0.0001$ for R550* vs Iso control;
1770 bottom: $p < 0.0001$ for Control vs R550*, $p < 0.0001$ for R550* vs Iso control.
1771
1772 (H & I) STED microscopy showed large-shifted punctum volume distribution of GW182 (red)
1773 in R550* iNeurons, in comparison to control and isogenic control iNeurons. Scale bar, 5 μ m.
1774 n=6 cells from 3 batches of experiments. Left: One-way ANOVA with Tukey's multiple
1775 comparisons test; Right: Two-way ANOVA with Sidak's multiple comparisons test on main
1776 effect of Control, R550* and Iso control; Multiple comparisons: top: $p < 0.0001$ for Control
1777 vs R550*, $p < 0.0001$ for R550* vs Iso control; bottom: $p < 0.0001$ for Control vs R550*, $p <$
1778 0.0001 for R550* vs Iso control.
1779
1780 (J) Co-immunoprecipitation of GW182 and ELAVL3-SE/SA from cytoplasmic extracts of
1781 HEK 293T cells. Immunoprecipitation was performed using an anti-GW182 antibody.
1782 ELAVL3 bands were revealed with an anti-ELAVL3 antibody.
1783
1784 (K) Quantification results of Co-immunoprecipitation, the GW182 capture more ELAVL3-
1785 SE than ELAVL3-SA. n=3 batches of experiments. Unpaired t-test (two-tailed). Data are
1786 presented as mean \pm SEM, * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$.
1787

Fig 5



1788
1789

1790 **Figure 5. CDKL5 modulate mRNA processing by regulating nELAVL condensates**

1791

1792 (A & B) FISH images of mRNA expression of *Fos* in ELAVL3-SE/SA expressing rat
1793 primary neurons. Compared to SE, ELAVL3-SA expressing neurons showed less *Fos* RNA
1794 puncta. Scale bar, 5 μ m. n=10 (SE) and 8 (SA) from 4 batches of experiments. Mann-Whitney
1795 test (two-tailed).

1796

1797 (C) EMSA showing different concentration of nELAVL-SE and -SA protein binding with
1798 *Fos* RNA. At higher protein concentration, the *Fos* RNA bound fraction in SE group is
1799 significantly higher than SA group. n=3. Two-way ANOVA with Sidak's multiple
1800 comparisons test.

1801

1802 (D & E) FISH images of mRNA expression of *Fos* in Control and R550* iNeurons after 2
1803 μ g/mL Actinomycin D (Act D) treatment. Compared to control group, CDD iNeurons
1804 showed shorter *Fos* mRNA half-life. Scale bar, 5 μ m. n=12 iNeurons from 3 batches of
1805 experiments. Two-way ANOVA with Sidak's multiple comparisons test on main effect of
1806 Control and R550*. Data are presented as mean \pm SEM, ** p < 0.01; **** p < 0.0001.


1807

1808

1809

1810

Fig 6



1811
1812
1813
1814

Figure 6. CDKL5 deletion leads to impaired visual function and nELAVL phosphorylation is necessary for visual processing.

1815 (A) Graphical design of the visual cliff task with measurements. Animals were placed on a
1816 platform (3 cm height) in the middle of the open field (left). Percentage of descents from the
1817 cliff side per mouse (5 trials per mouse) between WT and *Cdkl5* KO mice (right). WT: n=16
1818 mice, *Cdkl5* KO: n=16 mice. Mann-Whitney U test (two-tailed).
1819
1820 (B) Head-fixed wildtype control (WT) mice and *Cdkl5* KO were presented, either to one eye
1821 or both eyes, with visual stimuli of different directional grating patterns. In the binocular
1822 visual cortex (bV1), calcium signal in layer 2/3 (L2/3) neurons were live-imaged with two-
1823 photon laser microscopy.
1824
1825 (C) Field of views (FOVs) showing grating and natural scene responsive neurons in WT (left)
1826 and *Cdkl5* KO (right) mice. Scale bar, 20 μ m.
1827
1828 (D) Traces showing grating responsive neurons in WT and *Cdkl5* KO mice across 3 viewing
1829 conditions, which are binocular (Binoc), contralateral (Contra) and ipsilateral (Ipsi) viewing
1830 relatively to the brain hemisphere imaged. Yellow regions indicate grating presentation
1831 periods. Gray lines represent the Z-score from all trials and the colored lines show trial
1832 average.
1833
1834 (E) Boxplots showing the orientation selective index (OSI) of *Cdkl5* KO mice were reduced
1835 across Binoc, Contra and Ipsi conditions under grating (s.f. 0.08cpd). Binoc OSI: 870
1836 neurons from 6 WT and 698 neurons from 6 *Cdkl5* KO mice. Contra OSI: 794 neurons from
1837 6 WT and 693 neurons from 6 *Cdkl5* KO. Ipsi OSI: 629 neurons from 6 WT and 476 neurons
1838 from 6 *Cdkl5* KO. The centerlines represent median values, and the whiskers connect the
1839 nonoutlier minimum and maximum values to 0.25 and 0.75 quartiles respectively. Outliers
1840 are values greater than 1.5 interquartile range away from the quartiles. Mann-Whitney U test
1841 (two-tailed).
1842
1843 (F) Scatter plots comparing OSI and correlation of grating (s.f. 0.08cpd) responsive neurons
1844 in WT mice and *Cdkl5* KO mice. Color bar shows the correlation between tuning curves. 301
1845 neurons from 6 WT and 211 neurons from 6 *Cdkl5* KO. Mann-Whitney U test (two-tailed).
1846
1847 (G) Boxplots showing fraction of neurons per FOV within the blue region (OSI > 0.5) and
1848 red region (OSI < 0.5) from E. 26 FOV from 6 WT mice and 21 FOV from 6 *Cdkl5* KO mice.
1849 Mann-Whitney U test (two-tailed).
1850
1851 (H) Distribution of Contra and Ipsi eye correlation between WT and *Cdkl5* KO under grating
1852 (s.f. 0.08cpd) stimuli. 301 neurons from 6 WT and 211 neurons from 6 *Cdkl5* KO. Mann-
1853 Whitney U test (two-tailed).
1854
1855 (I) Distribution of difference in preferred orientation between WT and *Cdkl5* KO under
1856 grating (s.f. 0.08cpd) stimuli. 301 neurons from 6 WT and 211 neurons from 6 *Cdkl5* KO.
1857 Mann-Whitney U test (two-tailed).
1858
1859 (J) Traces showing natural scene responsive neurons in WT and *Cdkl5* KO mice across 3
1860 viewing conditions. Pink regions indicate natural scene presentation periods. Gray lines
1861 represent the Z-score from all trials and the colored lines show trial average.
1862

1863 (K) Distribution of contra and ipsi eye correlation between WT and *Cdk15* KO under natural
1864 scene stimuli. 529 neurons from 6 WT and 274 neurons from 6 *Cdk15* KO. Mann-Whitney U
1865 test (two-tailed).

1866

1867 (L) Mice were virally injected to express GCaMP6f (Ctrl), GCaMP6f and nELAVL (WT),
1868 GCaMP6f and nELAVL-SE (SE) or GCaMP6f and nELAVL-SA (SA). Head-fixed mice
1869 were presented, either to one eye or both eyes, with visual stimuli of different directional
1870 grating patterns and natural scene. In the binocular visual cortex (bV1), calcium signal in
1871 layer 2/3 (L2/3) neurons were live-imaged with two-photon laser microscopy.

1872

1873 (M) Boxplots showing OSI were reduced in WT, SE and SA mice across Binoc, Contra and
1874 Ipsi conditions under grating (s.f. 0.08cpd). Binoc OSI: 870 neurons from 6 Ctrl, 670 neurons
1875 from 5 WT injected, 532 neurons from 4 SE injected and 782 neurons from 5 SA injected
1876 mice. Contra OSI: 794 neurons from 6 Ctrl, 715 neurons from 5 WT injected, 500 neurons
1877 from 4 SE injected and 852 neurons from 5 SA injected mice. Ipsi OSI: 629 neurons from 6
1878 Ctrl, 574 neurons from 5 WT injected, 384 neurons from 4 SE injected and 613 neurons from
1879 5 SA injected mice. Kruskal-Wallis test followed by Tukey's multiple comparisons test.

1880

1881 (N) Boxplots showing Contra and Ipsi correlation under grating (s.f. 0.08cpd) stimuli in Ctrl,
1882 WT injected, SE injected and SA injected mice. 301 neurons from 6 Ctrl, 253 neurons from 5
1883 WT injected, 159 neurons from 4 SE injected and 275 neurons from 5 SA injected mice.
1884 Kruskal-Wallis test followed by Tukey's multiple comparisons test.

1885

1886 (O) Boxplots showing difference in preferred orientation under grating (s.f. 0.08cpd) stimuli
1887 in Ctrl, WT injected, SE injected and SA injected mice. 301 neurons from 6 Ctrl, 253 neurons
1888 from 5 WT injected, 159 neurons from 4 SE injected and 275 neurons from 5 SA injected
1889 mice. Kruskal-Wallis test followed by Tukey's multiple comparisons test.

1890

1891 (P) Boxplots showing Contra and Ipsi correlation under natural scene stimuli in Ctrl, WT
1892 injected, SE injected and SA injected mice. 529 neurons from 6 Ctrl, 185 neurons from 5 WT
1893 injected, 428 neurons from 4 SE injected and 443 neurons from 5 SA injected mice. Kruskal-
1894 Wallis test followed by Tukey's multiple comparisons test. Data are presented as mean \pm
1895 SEM, * $p < 0.05$. ** $p < 0.01$. *** $p < 0.001$. **** $p < 0.0001$.

1896